SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Unitedhealth Group Inc. – ‘10-Q’ for 6/30/20

On:  Friday, 7/31/20, at 8:03pm ET   ·   As of:  8/3/20   ·   For:  6/30/20   ·   Accession #:  731766-20-42   ·   File #:  1-10864

Previous ‘10-Q’:  ‘10-Q’ on 5/6/20 for 3/31/20   ·   Next:  ‘10-Q’ on 11/2/20 for 9/30/20   ·   Latest:  ‘10-Q’ on 11/6/23 for 9/30/23   ·   8 References:   

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 8/03/20  Unitedhealth Group Inc.           10-Q        6/30/20   56:13M

Quarterly Report   —   Form 10-Q
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML   1.20M 
 2: EX-10.2     Material Contract                                   HTML     70K 
 3: EX-10.3     Material Contract                                   HTML     69K 
 4: EX-10.4     Material Contract                                   HTML     67K 
 5: EX-10.5     Material Contract                                   HTML     34K 
 6: EX-31.1     Certification -- §302 - SOA'02                      HTML     27K 
 7: EX-32.1     Certification -- §906 - SOA'02                      HTML     20K 
14: R1          Document and Entity Information Document            HTML     71K 
15: R2          Condensed Consolidated Balance Sheets               HTML    121K 
16: R3          Condensed Consolidated Balance Sheet                HTML     32K 
                (Parenthetical)                                                  
17: R4          Condensed Consolidated Statements of Operations     HTML    103K 
18: R5          Condensed Consolidated Statements of Comprehensive  HTML     64K 
                Income                                                           
19: R6          Condensed Consolidated Statements of Changes in     HTML    104K 
                Equity                                                           
20: R7          Condensed Consolidated Statement of Changes in      HTML     21K 
                Equity (Parenthetical)                                           
21: R8          Condensed Consolidated Statements of Cash Flows     HTML    100K 
22: R9          Basis of Presentation (Notes)                       HTML     24K 
23: R10         Investments (Notes)                                 HTML    201K 
24: R11         Fair Value (Notes)                                  HTML    131K 
25: R12         Medical Costs Payable (Notes)                       HTML     40K 
26: R13         Short-Term Borrowings and Long-Term Debt (Notes)    HTML    281K 
27: R14         Dividends (Notes)                                   HTML     26K 
28: R15         Commitments and Contingencies (Notes)               HTML     24K 
29: R16         Segment Financial Information (Notes)               HTML    368K 
30: R17         Basis of Presentation Basis of Presentation         HTML     32K 
                (Policies)                                                       
31: R18         Investments (Policies)                              HTML     19K 
32: R19         Investments (Tables)                                HTML    200K 
33: R20         Fair Value (Tables)                                 HTML    132K 
34: R21         Medical Costs Payable (Tables)                      HTML     39K 
35: R22         Short-Term Borrowings and Long-Term Debt (Tables)   HTML    281K 
36: R23         Dividends (Tables)                                  HTML     24K 
37: R24         Segment Financial Information (Tables)              HTML    365K 
38: R25         Basis of Presentation Basis of Presentation, Uses   HTML     20K 
                of Estimates and Significant Accounting Policies                 
                (Details)                                                        
39: R26         Investments (Narrative) (Details)                   HTML     26K 
40: R27         Investments (Short-Term and Long-Term Investments)  HTML     68K 
                (Details)                                                        
41: R28         Investments (Amortized Cost and Fair Value of       HTML     86K 
                Available-for-Sale Debt Securities by Contractual                
                Maturity) (Details)                                              
42: R29         Investments (Fair Value of Available-For-Sale       HTML     53K 
                Investments with Gross Unrealized Losses by                      
                Investment Type and Length of Time That Individual               
                Securities Have Been in a Continuous Unrealized                  
                Loss Position) (Details)                                         
43: R30         Fair Value (Narrative) (Details)                    HTML     26K 
44: R31         Fair Value (Financial Assets and Liabilities        HTML     74K 
                Measured at Fair Value on a Recurring Basis)                     
                (Details)                                                        
45: R32         Fair Value (Financial Assets and Liabilities, Not   HTML     39K 
                Measured at Fair Value on a Recurring Basis)                     
                (Details)                                                        
46: R33         Medical Costs Payable (Narrative) (Details)         HTML     19K 
47: R34         Medical Costs Payable (Details)                     HTML     39K 
48: R35         Short-Term Borrowings and Long-Term Debt            HTML     46K 
                (Narrative) (Details)                                            
49: R36         Short-Term Borrowings and Long-Term Debt (Details)  HTML    199K 
50: R37         Dividends (Details)                                 HTML     21K 
51: R38         Segment Financial Information (Narrative)           HTML     19K 
                (Details)                                                        
52: R39         Segment Financial Information (Details)             HTML    102K 
54: XML         IDEA XML File -- Filing Summary                      XML     93K 
13: XML         XBRL Instance -- unh-20200630_htm                    XML   5.05M 
53: EXCEL       IDEA Workbook of Financial Reports                  XLSX     68K 
 9: EX-101.CAL  XBRL Calculations -- unh-20200630_cal                XML    195K 
10: EX-101.DEF  XBRL Definitions -- unh-20200630_def                 XML    505K 
11: EX-101.LAB  XBRL Labels -- unh-20200630_lab                      XML   1.22M 
12: EX-101.PRE  XBRL Presentations -- unh-20200630_pre               XML    717K 
 8: EX-101.SCH  XBRL Schema -- unh-20200630                          XSD    115K 
55: JSON        XBRL Instance as JSON Data -- MetaLinks              304±   436K 
56: ZIP         XBRL Zipped Folder -- 0000731766-20-000042-xbrl      Zip    365K

‘10-Q’   —   Quarterly Report
Document Table of Contents

Page (sequential)   (alphabetic) ↑Top
 
11st Page  –  Filing Submission
"Table of Contents
"Part I. Financial Information
"Item 1
"Financial Statements (unaudited)
"Condensed Consolidated Balance Sheets as of
"June
"2020 and December 31, 2019
"Condensed Consolidated Statements of Operations for the Thre
"E and Six
"Onths Ended
"2020 and 2019
"Condensed Consolidated Statements of Comprehensive Income for the Three
"And Six
"Months Ended
"Condensed Consolidated Statements of Changes in Equity for the Three
"Nd Six
"Condensed Consolidated Statements of Cash Flows for the
"Six
"Notes to the Condensed Consolidated Financial Statements
"Basis of Presentation
"Note 1 of Notes to the Condensed Consolidated Financial Statements
"Investments
"Fair Value
"Medical Costs Payable
"Short-Term Borrowings and Long-Term Debt
"Note 5 of Notes to the Condensed Consolidated Financial Statements
"Dividends
"Note 6 of Notes to the Condensed Consolidated Fina
"Ncial Statements
"Commitments and Contingencies
"Note 7 of Notes to the Condensed Consolidated Financial Statements
"Segment Financial Information
"Note 8 of Notes to the Condensed Consolidated Financial Statements
"Item 2
"Management's Discussion and Analysis of Financial Condition and Results of Operations
"Item 3
"Quantitative and Qualitative Disclosures About Market Risk
"Item 4
"Controls and Procedures
"Part II. Other Information
"Legal Proceedings
"Item 1A
"Risk Factors
"Unregistered Sales of Equity Securities and Use of Proceeds
"Item 6
"Exhibits
"Signatures

This is an HTML Document rendered as filed.  [ Alternative Formats ]

 iX:   C:  C: 
  unh-20200630  
 i false i 2020 i Q2 i 0000731766 i 12/31 i 950,335,762 i 0.01 i 0.01 i 3,000 i 3,000 i 950 i 948 i 950 i 948 i 0.001 i 0.001 i 10 i 10 i — i — i — i — i 1.25 i 1.08 i 2.33 i 1.98 i True i 2.0 i 1.4 i — i — i — i — i — i — i 0.06875 i 0.05700 i 0.05950 i 0.02700 i 0.04625 i 0.04375 i 0.03875 i 0.0395 i 0.01950 i 0.0425 i 0.04700 i 0.0475 i 0.02125 i 0.04200 i 0.04250 i 0.03150 i 0.03750 i 0.03375 i 0.04250 i 0.02875 i 0.04450 i 0.02875 i 0.02375 i 0.03350 i 0.02875 i 0.02375 i 0.03500 i — i 0.03700 i 0.02750 i 0.03875 i 0.02875 i 0.01250 i 0.03500 i 0.02000 i 0.03500 i 0.02750 i 0.03750 i 0.02900 i 0.03700 i 0.03125 i 0.03100 i 0.03450 i 0.03375 i 0.02950 i 0.03850 i 0.03875 i 0.04625 i 0.05800 i 0.06500 i 0.06625 i 5 i 3 i 36400007317662020-01-012020-06-30xbrli:shares00007317662020-07-30iso4217:USD00007317662020-06-3000007317662019-12-31iso4217:USDxbrli:shares00007317662020-04-012020-06-3000007317662019-04-012019-06-3000007317662019-01-012019-06-300000731766us-gaap:CommonStockMember2020-03-310000731766us-gaap:AdditionalPaidInCapitalMember2020-03-310000731766us-gaap:RetainedEarningsMember2020-03-310000731766us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-03-310000731766us-gaap:AccumulatedTranslationAdjustmentMember2020-03-310000731766us-gaap:NoncontrollingInterestMember2020-03-3100007317662020-03-310000731766us-gaap:RetainedEarningsMember2020-04-012020-06-300000731766us-gaap:NoncontrollingInterestMember2020-04-012020-06-300000731766us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-04-012020-06-300000731766us-gaap:AccumulatedTranslationAdjustmentMember2020-04-012020-06-300000731766us-gaap:CommonStockMember2020-04-012020-06-300000731766us-gaap:AdditionalPaidInCapitalMember2020-04-012020-06-300000731766us-gaap:CommonStockMember2020-06-300000731766us-gaap:AdditionalPaidInCapitalMember2020-06-300000731766us-gaap:RetainedEarningsMember2020-06-300000731766us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-06-300000731766us-gaap:AccumulatedTranslationAdjustmentMember2020-06-300000731766us-gaap:NoncontrollingInterestMember2020-06-300000731766us-gaap:CommonStockMember2019-03-310000731766us-gaap:AdditionalPaidInCapitalMember2019-03-310000731766us-gaap:RetainedEarningsMember2019-03-310000731766us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-03-310000731766us-gaap:AccumulatedTranslationAdjustmentMember2019-03-310000731766us-gaap:NoncontrollingInterestMember2019-03-3100007317662019-03-310000731766us-gaap:RetainedEarningsMember2019-04-012019-06-300000731766us-gaap:NoncontrollingInterestMember2019-04-012019-06-300000731766us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-04-012019-06-300000731766us-gaap:AccumulatedTranslationAdjustmentMember2019-04-012019-06-300000731766us-gaap:CommonStockMember2019-04-012019-06-300000731766us-gaap:AdditionalPaidInCapitalMember2019-04-012019-06-300000731766us-gaap:CommonStockMember2019-06-300000731766us-gaap:AdditionalPaidInCapitalMember2019-06-300000731766us-gaap:RetainedEarningsMember2019-06-300000731766us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-06-300000731766us-gaap:AccumulatedTranslationAdjustmentMember2019-06-300000731766us-gaap:NoncontrollingInterestMember2019-06-3000007317662019-06-300000731766us-gaap:CommonStockMember2019-12-310000731766us-gaap:AdditionalPaidInCapitalMember2019-12-310000731766us-gaap:RetainedEarningsMember2019-12-310000731766us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-12-310000731766us-gaap:AccumulatedTranslationAdjustmentMember2019-12-310000731766us-gaap:NoncontrollingInterestMember2019-12-310000731766us-gaap:RetainedEarningsMemberus-gaap:AccountingStandardsUpdate201613Member2019-12-310000731766us-gaap:AccountingStandardsUpdate201613Member2019-12-310000731766us-gaap:RetainedEarningsMember2020-01-012020-06-300000731766us-gaap:NoncontrollingInterestMember2020-01-012020-06-300000731766us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-01-012020-06-300000731766us-gaap:AccumulatedTranslationAdjustmentMember2020-01-012020-06-300000731766us-gaap:CommonStockMember2020-01-012020-06-300000731766us-gaap:AdditionalPaidInCapitalMember2020-01-012020-06-300000731766us-gaap:CommonStockMember2018-12-310000731766us-gaap:AdditionalPaidInCapitalMember2018-12-310000731766us-gaap:RetainedEarningsMember2018-12-310000731766us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2018-12-310000731766us-gaap:AccumulatedTranslationAdjustmentMember2018-12-310000731766us-gaap:NoncontrollingInterestMember2018-12-3100007317662018-12-310000731766us-gaap:RetainedEarningsMemberus-gaap:AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember2018-12-310000731766us-gaap:NoncontrollingInterestMemberus-gaap:AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember2018-12-310000731766us-gaap:AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember2018-12-310000731766us-gaap:RetainedEarningsMember2019-01-012019-06-300000731766us-gaap:NoncontrollingInterestMember2019-01-012019-06-300000731766us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-01-012019-06-300000731766us-gaap:AccumulatedTranslationAdjustmentMember2019-01-012019-06-300000731766us-gaap:CommonStockMember2019-01-012019-06-300000731766us-gaap:AdditionalPaidInCapitalMember2019-01-012019-06-300000731766us-gaap:AccountingStandardsUpdate201613Member2020-01-010000731766us-gaap:USTreasuryAndGovernmentMember2020-06-300000731766us-gaap:USStatesAndPoliticalSubdivisionsMember2020-06-300000731766us-gaap:CorporateDebtSecuritiesMember2020-06-300000731766us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember2020-06-300000731766us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember2020-06-300000731766us-gaap:USTreasuryAndGovernmentMember2019-12-310000731766us-gaap:USStatesAndPoliticalSubdivisionsMember2019-12-310000731766us-gaap:CorporateDebtSecuritiesMember2019-12-310000731766us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember2019-12-310000731766us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember2019-12-310000731766us-gaap:DebtSecuritiesMember2020-06-300000731766us-gaap:DebtSecuritiesMember2019-12-31xbrli:pure0000731766us-gaap:FairValueInputsLevel1Member2020-06-300000731766us-gaap:FairValueInputsLevel2Member2020-06-300000731766us-gaap:FairValueInputsLevel3Member2020-06-300000731766us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel1Member2020-06-300000731766us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel2Member2020-06-300000731766us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel3Member2020-06-300000731766us-gaap:USStatesAndPoliticalSubdivisionsMemberus-gaap:FairValueInputsLevel1Member2020-06-300000731766us-gaap:USStatesAndPoliticalSubdivisionsMemberus-gaap:FairValueInputsLevel2Member2020-06-300000731766us-gaap:USStatesAndPoliticalSubdivisionsMemberus-gaap:FairValueInputsLevel3Member2020-06-300000731766us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMember2020-06-300000731766us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2020-06-300000731766us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMember2020-06-300000731766us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMemberus-gaap:FairValueInputsLevel1Member2020-06-300000731766us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMemberus-gaap:FairValueInputsLevel2Member2020-06-300000731766us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMemberus-gaap:FairValueInputsLevel3Member2020-06-300000731766us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMemberus-gaap:FairValueInputsLevel1Member2020-06-300000731766us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMemberus-gaap:FairValueInputsLevel2Member2020-06-300000731766us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMemberus-gaap:FairValueInputsLevel3Member2020-06-300000731766us-gaap:FairValueInputsLevel1Memberus-gaap:DebtSecuritiesMember2020-06-300000731766us-gaap:FairValueInputsLevel2Memberus-gaap:DebtSecuritiesMember2020-06-300000731766us-gaap:DebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2020-06-300000731766us-gaap:FairValueInputsLevel1Member2019-12-310000731766us-gaap:FairValueInputsLevel2Member2019-12-310000731766us-gaap:FairValueInputsLevel3Member2019-12-310000731766us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel1Member2019-12-310000731766us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel2Member2019-12-310000731766us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel3Member2019-12-310000731766us-gaap:USStatesAndPoliticalSubdivisionsMemberus-gaap:FairValueInputsLevel1Member2019-12-310000731766us-gaap:USStatesAndPoliticalSubdivisionsMemberus-gaap:FairValueInputsLevel2Member2019-12-310000731766us-gaap:USStatesAndPoliticalSubdivisionsMemberus-gaap:FairValueInputsLevel3Member2019-12-310000731766us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMember2019-12-310000731766us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2019-12-310000731766us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMember2019-12-310000731766us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMemberus-gaap:FairValueInputsLevel1Member2019-12-310000731766us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMemberus-gaap:FairValueInputsLevel2Member2019-12-310000731766us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMemberus-gaap:FairValueInputsLevel3Member2019-12-310000731766us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMemberus-gaap:FairValueInputsLevel1Member2019-12-310000731766us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMemberus-gaap:FairValueInputsLevel2Member2019-12-310000731766us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMemberus-gaap:FairValueInputsLevel3Member2019-12-310000731766us-gaap:FairValueInputsLevel1Memberus-gaap:DebtSecuritiesMember2019-12-310000731766us-gaap:FairValueInputsLevel2Memberus-gaap:DebtSecuritiesMember2019-12-310000731766us-gaap:DebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2019-12-310000731766us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsNonrecurringMember2020-06-300000731766us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsNonrecurringMember2020-06-300000731766us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsNonrecurringMember2020-06-300000731766us-gaap:FairValueMeasurementsNonrecurringMember2020-06-300000731766us-gaap:LongTermDebtMember2020-06-300000731766us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsNonrecurringMember2019-12-310000731766us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsNonrecurringMember2019-12-310000731766us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsNonrecurringMember2019-12-310000731766us-gaap:FairValueMeasurementsNonrecurringMember2019-12-310000731766us-gaap:LongTermDebtMember2019-12-310000731766us-gaap:FairValueMeasurementsNonrecurringMember2020-01-012020-06-300000731766us-gaap:FairValueMeasurementsNonrecurringMember2019-01-012019-06-300000731766us-gaap:CommercialPaperMember2020-06-300000731766us-gaap:CommercialPaperMember2019-12-310000731766unh:A2.700NotesdueJuly2020Member2020-06-300000731766unh:A2.700NotesdueJuly2020Member2019-12-310000731766unh:FloatingratenotesdueOctober2020Member2020-06-300000731766unh:FloatingratenotesdueOctober2020Member2019-12-310000731766unh:A3.875notesdueOctober2020Member2020-06-300000731766unh:A3.875notesdueOctober2020Member2019-12-310000731766unh:A1.950notesdueOctober2020Member2020-06-300000731766unh:A1.950notesdueOctober2020Member2019-12-310000731766unh:A4.700notesdueFebruary2021Member2020-06-300000731766unh:A4.700notesdueFebruary2021Member2019-12-310000731766unh:A2.125notesdueMarch2021Member2020-06-300000731766unh:A2.125notesdueMarch2021Member2019-12-310000731766unh:FloatingratenotesdueJune2021Member2020-06-300000731766unh:FloatingratenotesdueJune2021Member2019-12-310000731766unh:A3.150notesdueJune2021Member2020-06-300000731766unh:A3.150notesdueJune2021Member2019-12-310000731766unh:A3.375notesdueNovember2021Member2020-06-300000731766unh:A3.375notesdueNovember2021Member2019-12-310000731766unh:A2.875notesdueDecember2021Member2020-06-300000731766unh:A2.875notesdueDecember2021Member2019-12-310000731766unh:A2.875notesdueMarch2022Member2020-06-300000731766unh:A2.875notesdueMarch2022Member2019-12-310000731766unh:A3.350notesdueJuly2022Member2020-06-300000731766unh:A3.350notesdueJuly2022Member2019-12-310000731766unh:A2.375notesdueOctober2022MemberMember2020-06-300000731766unh:A2.375notesdueOctober2022MemberMember2019-12-310000731766unh:ZeroCouponnotesdueNovember2022Member2020-06-300000731766unh:ZeroCouponnotesdueNovember2022Member2019-12-310000731766unh:A2.750notesdueFebruary2023Member2020-06-300000731766unh:A2.750notesdueFebruary2023Member2019-12-310000731766unh:A2.875notesdueMarch2023Member2020-06-300000731766unh:A2.875notesdueMarch2023Member2019-12-310000731766unh:A3.500notesdueJune2023Member2020-06-300000731766unh:A3.500notesdueJune2023Member2019-12-310000731766unh:A3.500notesdueFebruary2024Member2020-06-300000731766unh:A3.500notesdueFebruary2024Member2019-12-310000731766unh:A2.375notesdueAugust2024Member2020-06-300000731766unh:A2.375notesdueAugust2024Member2019-12-310000731766unh:A3.750notesdueJuly2025Member2020-06-300000731766unh:A3.750notesdueJuly2025Member2019-12-310000731766unh:A3.700notesdueDecember2025Member2020-06-300000731766unh:A3.700notesdueDecember2025Member2019-12-310000731766unh:A1250NotesDueJanuary2026Member2020-06-300000731766unh:A1250NotesDueJanuary2026Member2019-12-310000731766unh:A3.100notesdueMarch2026Member2020-06-300000731766unh:A3.100notesdueMarch2026Member2019-12-310000731766unh:A3.450notesdueJanuary2027Member2020-06-300000731766unh:A3.450notesdueJanuary2027Member2019-12-310000731766unh:A3.375notesdueApril2027Member2020-06-300000731766unh:A3.375notesdueApril2027Member2019-12-310000731766unh:A2.950notesdueOctober2027Member2020-06-300000731766unh:A2.950notesdueOctober2027Member2019-12-310000731766unh:A3.850notesdueJune2028Member2020-06-300000731766unh:A3.850notesdueJune2028Member2019-12-310000731766unh:A3.875notesdueDecember2028Member2020-06-300000731766unh:A3.875notesdueDecember2028Member2019-12-310000731766unh:A2.875notesdueAugust2029Member2020-06-300000731766unh:A2.875notesdueAugust2029Member2019-12-310000731766unh:A2000NotesDueMay2030Member2020-06-300000731766unh:A2000NotesDueMay2030Member2019-12-310000731766unh:A4.625notesdueJuly2035Member2020-06-300000731766unh:A4.625notesdueJuly2035Member2019-12-310000731766unh:A5.800notesdueMarch2036Member2020-06-300000731766unh:A5.800notesdueMarch2036Member2019-12-310000731766unh:A6.500NotesDueJune2037MemberMember2020-06-300000731766unh:A6.500NotesDueJune2037MemberMember2019-12-310000731766unh:A6.625NotesdueNovember2037Member2020-06-300000731766unh:A6.625NotesdueNovember2037Member2019-12-310000731766unh:A6.875notesdueFebruary2038Member2020-06-300000731766unh:A6.875notesdueFebruary2038Member2019-12-310000731766unh:A3.500notesdueAugust2039Member2020-06-300000731766unh:A3.500notesdueAugust2039Member2019-12-310000731766unh:A2750NotesDueMay2040Member2020-06-300000731766unh:A2750NotesDueMay2040Member2019-12-310000731766unh:A5.700notesdueOctober2040Member2020-06-300000731766unh:A5.700notesdueOctober2040Member2019-12-310000731766unh:A5.950notesdueFebruary2041Member2020-06-300000731766unh:A5.950notesdueFebruary2041Member2019-12-310000731766unh:A4.625notesdueNovember2041Member2020-06-300000731766unh:A4.625notesdueNovember2041Member2019-12-310000731766unh:A4.375notesdueMarch2042Member2020-06-300000731766unh:A4.375notesdueMarch2042Member2019-12-310000731766unh:A3.950notesdueOctober2042Member2020-06-300000731766unh:A3.950notesdueOctober2042Member2019-12-310000731766unh:A4.250notesdueMarch2043Member2020-06-300000731766unh:A4.250notesdueMarch2043Member2019-12-310000731766unh:A4.750notesdueJuly2045Member2020-06-300000731766unh:A4.750notesdueJuly2045Member2019-12-310000731766unh:A4.200notesdueJanuary2047Member2020-06-300000731766unh:A4.200notesdueJanuary2047Member2019-12-310000731766unh:A4.250notesdueApril2047Member2020-06-300000731766unh:A4.250notesdueApril2047Member2019-12-310000731766unh:A3.750notesdueOctober2047Member2020-06-300000731766unh:A3.750notesdueOctober2047Member2019-12-310000731766unh:A4.250notesdueJune2048Member2020-06-300000731766unh:A4.250notesdueJune2048Member2019-12-310000731766unh:A4.450notesdueDecember2048Member2020-06-300000731766unh:A4.450notesdueDecember2048Member2019-12-310000731766unh:A3.700notesdueAugust2049Member2020-06-300000731766unh:A3.700notesdueAugust2049Member2019-12-310000731766unh:A2900NotesDueMay2050Member2020-06-300000731766unh:A2900NotesDueMay2050Member2019-12-310000731766unh:A3.875notesdueAugust2059Member2020-06-300000731766unh:A3.875notesdueAugust2059Member2019-12-310000731766unh:A3125NotesDueMay2060Member2020-06-300000731766unh:A3125NotesDueMay2060Member2019-12-310000731766srt:SubsidiariesMember2020-06-300000731766srt:SubsidiariesMember2019-12-310000731766unh:Fiveyear4.4billioncreditfacilityMemberus-gaap:RevolvingCreditFacilityMember2020-06-300000731766unh:Threeyear4.4billioncreditfacilityMemberus-gaap:RevolvingCreditFacilityMember2020-06-300000731766us-gaap:RevolvingCreditFacilityMemberunh:A364day3.8billioncreditfacilityMember2020-06-300000731766us-gaap:RevolvingCreditFacilityMembersrt:MinimumMember2020-06-300000731766us-gaap:RevolvingCreditFacilityMembersrt:MaximumMember2020-06-300000731766unh:Fiveyear4.4billioncreditfacilityMemberus-gaap:RevolvingCreditFacilityMember2020-01-012020-06-300000731766unh:Threeyear4.4billioncreditfacilityMemberus-gaap:RevolvingCreditFacilityMember2020-01-012020-06-300000731766us-gaap:RevolvingCreditFacilityMemberunh:A364day3.8billioncreditfacilityMember2020-01-012020-06-3000007317662020-03-242020-03-2400007317662020-06-302020-06-30unh:reportableSegments0000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberunh:UnitedhealthcareMember2020-04-012020-06-300000731766unh:OptumhealthMemberunh:ExternalCustomersMemberus-gaap:OperatingSegmentsMember2020-04-012020-06-300000731766unh:OptuminsightMemberunh:ExternalCustomersMemberus-gaap:OperatingSegmentsMember2020-04-012020-06-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberunh:OptumrxMember2020-04-012020-06-300000731766unh:ExternalCustomersMemberus-gaap:IntersegmentEliminationMember2020-04-012020-06-300000731766unh:ExternalCustomersMemberunh:TotalOptumMember2020-04-012020-06-300000731766us-gaap:CorporateNonSegmentMemberunh:ExternalCustomersMember2020-04-012020-06-300000731766unh:ExternalCustomersMember2020-04-012020-06-300000731766unh:IntersegmentMemberus-gaap:OperatingSegmentsMemberunh:UnitedhealthcareMember2020-04-012020-06-300000731766unh:IntersegmentMemberunh:OptumhealthMemberus-gaap:OperatingSegmentsMember2020-04-012020-06-300000731766unh:IntersegmentMemberunh:OptuminsightMemberus-gaap:OperatingSegmentsMember2020-04-012020-06-300000731766unh:IntersegmentMemberus-gaap:OperatingSegmentsMemberunh:OptumrxMember2020-04-012020-06-300000731766unh:IntersegmentMemberus-gaap:IntersegmentEliminationMember2020-04-012020-06-300000731766unh:IntersegmentMemberunh:TotalOptumMember2020-04-012020-06-300000731766unh:IntersegmentMemberus-gaap:CorporateNonSegmentMember2020-04-012020-06-300000731766unh:IntersegmentMember2020-04-012020-06-300000731766us-gaap:OperatingSegmentsMemberunh:UnitedhealthcareMember2020-04-012020-06-300000731766unh:OptumhealthMemberus-gaap:OperatingSegmentsMember2020-04-012020-06-300000731766unh:OptuminsightMemberus-gaap:OperatingSegmentsMember2020-04-012020-06-300000731766us-gaap:OperatingSegmentsMemberunh:OptumrxMember2020-04-012020-06-300000731766us-gaap:IntersegmentEliminationMember2020-04-012020-06-300000731766unh:TotalOptumMember2020-04-012020-06-300000731766us-gaap:CorporateNonSegmentMember2020-04-012020-06-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberunh:UnitedhealthcareMember2019-04-012019-06-300000731766unh:OptumhealthMemberunh:ExternalCustomersMemberus-gaap:OperatingSegmentsMember2019-04-012019-06-300000731766unh:OptuminsightMemberunh:ExternalCustomersMemberus-gaap:OperatingSegmentsMember2019-04-012019-06-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberunh:OptumrxMember2019-04-012019-06-300000731766unh:ExternalCustomersMemberus-gaap:IntersegmentEliminationMember2019-04-012019-06-300000731766unh:ExternalCustomersMemberunh:TotalOptumMember2019-04-012019-06-300000731766us-gaap:CorporateNonSegmentMemberunh:ExternalCustomersMember2019-04-012019-06-300000731766unh:ExternalCustomersMember2019-04-012019-06-300000731766unh:IntersegmentMemberus-gaap:OperatingSegmentsMemberunh:UnitedhealthcareMember2019-04-012019-06-300000731766unh:IntersegmentMemberunh:OptumhealthMemberus-gaap:OperatingSegmentsMember2019-04-012019-06-300000731766unh:IntersegmentMemberunh:OptuminsightMemberus-gaap:OperatingSegmentsMember2019-04-012019-06-300000731766unh:IntersegmentMemberus-gaap:OperatingSegmentsMemberunh:OptumrxMember2019-04-012019-06-300000731766unh:IntersegmentMemberus-gaap:IntersegmentEliminationMember2019-04-012019-06-300000731766unh:IntersegmentMemberunh:TotalOptumMember2019-04-012019-06-300000731766unh:IntersegmentMemberus-gaap:CorporateNonSegmentMember2019-04-012019-06-300000731766unh:IntersegmentMember2019-04-012019-06-300000731766us-gaap:OperatingSegmentsMemberunh:UnitedhealthcareMember2019-04-012019-06-300000731766unh:OptumhealthMemberus-gaap:OperatingSegmentsMember2019-04-012019-06-300000731766unh:OptuminsightMemberus-gaap:OperatingSegmentsMember2019-04-012019-06-300000731766us-gaap:OperatingSegmentsMemberunh:OptumrxMember2019-04-012019-06-300000731766us-gaap:IntersegmentEliminationMember2019-04-012019-06-300000731766unh:TotalOptumMember2019-04-012019-06-300000731766us-gaap:CorporateNonSegmentMember2019-04-012019-06-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberunh:UnitedhealthcareMember2020-01-012020-06-300000731766unh:OptumhealthMemberunh:ExternalCustomersMemberus-gaap:OperatingSegmentsMember2020-01-012020-06-300000731766unh:OptuminsightMemberunh:ExternalCustomersMemberus-gaap:OperatingSegmentsMember2020-01-012020-06-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberunh:OptumrxMember2020-01-012020-06-300000731766unh:ExternalCustomersMemberus-gaap:IntersegmentEliminationMember2020-01-012020-06-300000731766unh:ExternalCustomersMemberunh:TotalOptumMember2020-01-012020-06-300000731766us-gaap:CorporateNonSegmentMemberunh:ExternalCustomersMember2020-01-012020-06-300000731766unh:ExternalCustomersMember2020-01-012020-06-300000731766unh:IntersegmentMemberus-gaap:OperatingSegmentsMemberunh:UnitedhealthcareMember2020-01-012020-06-300000731766unh:IntersegmentMemberunh:OptumhealthMemberus-gaap:OperatingSegmentsMember2020-01-012020-06-300000731766unh:IntersegmentMemberunh:OptuminsightMemberus-gaap:OperatingSegmentsMember2020-01-012020-06-300000731766unh:IntersegmentMemberus-gaap:OperatingSegmentsMemberunh:OptumrxMember2020-01-012020-06-300000731766unh:IntersegmentMemberus-gaap:IntersegmentEliminationMember2020-01-012020-06-300000731766unh:IntersegmentMemberunh:TotalOptumMember2020-01-012020-06-300000731766unh:IntersegmentMemberus-gaap:CorporateNonSegmentMember2020-01-012020-06-300000731766unh:IntersegmentMember2020-01-012020-06-300000731766us-gaap:OperatingSegmentsMemberunh:UnitedhealthcareMember2020-01-012020-06-300000731766unh:OptumhealthMemberus-gaap:OperatingSegmentsMember2020-01-012020-06-300000731766unh:OptuminsightMemberus-gaap:OperatingSegmentsMember2020-01-012020-06-300000731766us-gaap:OperatingSegmentsMemberunh:OptumrxMember2020-01-012020-06-300000731766us-gaap:IntersegmentEliminationMember2020-01-012020-06-300000731766unh:TotalOptumMember2020-01-012020-06-300000731766us-gaap:CorporateNonSegmentMember2020-01-012020-06-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberunh:UnitedhealthcareMember2019-01-012019-06-300000731766unh:OptumhealthMemberunh:ExternalCustomersMemberus-gaap:OperatingSegmentsMember2019-01-012019-06-300000731766unh:OptuminsightMemberunh:ExternalCustomersMemberus-gaap:OperatingSegmentsMember2019-01-012019-06-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberunh:OptumrxMember2019-01-012019-06-300000731766unh:ExternalCustomersMemberus-gaap:IntersegmentEliminationMember2019-01-012019-06-300000731766unh:ExternalCustomersMemberunh:TotalOptumMember2019-01-012019-06-300000731766us-gaap:CorporateNonSegmentMemberunh:ExternalCustomersMember2019-01-012019-06-300000731766unh:ExternalCustomersMember2019-01-012019-06-300000731766unh:IntersegmentMemberus-gaap:OperatingSegmentsMemberunh:UnitedhealthcareMember2019-01-012019-06-300000731766unh:IntersegmentMemberunh:OptumhealthMemberus-gaap:OperatingSegmentsMember2019-01-012019-06-300000731766unh:IntersegmentMemberunh:OptuminsightMemberus-gaap:OperatingSegmentsMember2019-01-012019-06-300000731766unh:IntersegmentMemberus-gaap:OperatingSegmentsMemberunh:OptumrxMember2019-01-012019-06-300000731766unh:IntersegmentMemberus-gaap:IntersegmentEliminationMember2019-01-012019-06-300000731766unh:IntersegmentMemberunh:TotalOptumMember2019-01-012019-06-300000731766unh:IntersegmentMemberus-gaap:CorporateNonSegmentMember2019-01-012019-06-300000731766unh:IntersegmentMember2019-01-012019-06-300000731766us-gaap:OperatingSegmentsMemberunh:UnitedhealthcareMember2019-01-012019-06-300000731766unh:OptumhealthMemberus-gaap:OperatingSegmentsMember2019-01-012019-06-300000731766unh:OptuminsightMemberus-gaap:OperatingSegmentsMember2019-01-012019-06-300000731766us-gaap:OperatingSegmentsMemberunh:OptumrxMember2019-01-012019-06-300000731766us-gaap:IntersegmentEliminationMember2019-01-012019-06-300000731766unh:TotalOptumMember2019-01-012019-06-300000731766us-gaap:CorporateNonSegmentMember2019-01-012019-06-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________________________________________________ 
Form  i 10-Q
__________________________________________________________ 
 i ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED  i June 30, 2020
or
 i ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM _______ TO _______
Commission File Number:  i 1-10864
__________________________________________________________ 
unh-20200630_g1.jpg
 i UnitedHealth Group Incorporated
(Exact name of registrant as specified in its charter)
 __________________________________________________________ 
 i Delaware  i 41-1321939
(State or other jurisdiction of
incorporation or organization)		 (I.R.S. Employer
Identification No.)
 i UnitedHealth Group Center  i 55343
 i 9900 Bren Road East
 i Minnetonka,
 i Minnesota
(Address of principal executive offices) (Zip Code)
( i 952)  i 936-1300
(Registrant’s telephone number, including area code)
_________________________________________________________  
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
 i Common Stock, $.01 par value i UNH i NYSE
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     i Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     i Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act
 i Large accelerated filer☒Accelerated filer
☐
Non-accelerated filer
☐
Smaller reporting company
 i ☐
Emerging growth company
 i ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  i ☐ No ☒
As of July 30, 2020, there were  i 950,335,762 shares of the registrant’s Common Stock, $.01 par value per share, issued and outstanding.


UNITEDHEALTH GROUP
Table of Contents
 
  Page
1
Condensed Consolidated Balance Sheets as of June 30, 2020 and December 31, 2019
1
Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2020 and 2019
2
Condensed Consolidated Statements of Comprehensive Income for the Three and Six Months Ended June 30, 2020 and 2019
3
Condensed Consolidated Statements of Changes in Equity for the Three and Six Months Ended June 30, 2020 and 2019
4
Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2020 and 2019
6
Notes to the Condensed Consolidated Financial Statements
7
7
8
10
11
12
13
13
14
16
25
25
25
26
26
27
28



PART I
ITEM 1. FINANCIAL STATEMENTS
UnitedHealth Group
Condensed Consolidated Balance Sheets
(Unaudited)
(in millions, except per share data)June 30,
2020		December 31,
2019
Assets
Current assets:
Cash and cash equivalents$ i 22,327  $ i 10,985  
Short-term investments i 3,266   i 3,260  
Accounts receivable, net i 12,546   i 11,822  
Other current receivables, net i 11,430   i 9,640  
Assets under management i 3,417   i 3,076  
Prepaid expenses and other current assets i 5,932   i 3,851  
Total current assets i 58,918   i 42,634  
Long-term investments i 36,778   i 37,209  
Property, equipment and capitalized software, net
 i 8,126   i 8,704  
Goodwill i 67,872   i 65,659  
Other intangible assets, net i 10,552   i 10,349  
Other assets i 10,237   i 9,334  
Total assets$ i 192,483  $ i 173,889  
Liabilities, redeemable noncontrolling interests and equity
Current liabilities:
Medical costs payable$ i 19,200  $ i 21,690  
Accounts payable and accrued liabilities i 25,423   i 19,005  
Short-term borrowings and current maturities of long-term debt i 6,156   i 3,870  
Unearned revenues i 2,299   i 2,622  
Other current liabilities i 16,805   i 14,595  
Total current liabilities i 69,883   i 61,782  
Long-term debt, less current maturities i 39,901   i 36,808  
Deferred income taxes i 3,286   i 2,993  
Other liabilities i 11,056   i 10,144  
Total liabilities i 124,126   i 111,727  
Commitments and contingencies (Note 7) i  i 
Redeemable noncontrolling interests i 1,842   i 1,726  
Equity:
Preferred stock, $0.001 par value - 10 shares authorized; no shares issued or outstanding
 i —   i —  
Common stock, $0.01 par value - 3,000 shares authorized; 950 and 948 issued and outstanding
 i 10   i 9  
Additional paid-in capital i 388   i 7  
Retained earnings i 67,776   i 61,178  
Accumulated other comprehensive loss( i 4,550) ( i 3,578) 
Nonredeemable noncontrolling interests
 i 2,891   i 2,820  
Total equity i 66,515   i 60,436  
Total liabilities, redeemable noncontrolling interests and equity$ i 192,483  $ i 173,889  
See Notes to the Condensed Consolidated Financial Statements
1
Table of Contents
UnitedHealth Group
Condensed Consolidated Statements of Operations
(Unaudited)
 Three Months Ended
June 30,		Six Months Ended
June 30,
(in millions, except per share data)2020201920202019
Revenues:
Premiums$ i 49,394  $ i 47,164  $ i 100,034  $ i 94,677  
Products i 8,247   i 8,353   i 16,678   i 16,425  
Services i 4,156   i 4,496   i 9,141   i 8,814  
Investment and other income i 341   i 582   i 706   i 987  
Total revenues i 62,138   i 60,595   i 126,559   i 120,903  
Operating costs:
Medical costs i 34,678   i 39,184   i 75,678   i 78,123  
Operating costs i 10,001   i 8,415   i 20,016   i 16,932  
Cost of products sold i 7,501   i 7,598   i 15,188   i 14,979  
Depreciation and amortization i 717   i 654   i 1,440   i 1,293  
Total operating costs i 52,897   i 55,851   i 112,322   i 111,327  
Earnings from operations i 9,241   i 4,744   i 14,237   i 9,576  
Interest expense( i 430) ( i 418) ( i 867) ( i 818) 
Earnings before income taxes i 8,811   i 4,326   i 13,370   i 8,758  
Provision for income taxes( i 2,115) ( i 941) ( i 3,209) ( i 1,816) 
Net earnings i 6,696   i 3,385   i 10,161   i 6,942  
Earnings attributable to noncontrolling interests( i 59) ( i 92) ( i 142) ( i 182) 
Net earnings attributable to UnitedHealth Group common shareholders
 i 6,637   i 3,293  $ i 10,019  $ i 6,760  
Earnings per share attributable to UnitedHealth Group common shareholders:
Basic
$ i 6.99  $ i 3.47  $ i 10.56  $ i 7.09  
Diluted
$ i 6.91  $ i 3.42  $ i 10.43  $ i 6.97  
Basic weighted-average number of common shares outstanding
 i 949   i 950   i 949   i 954  
Dilutive effect of common share equivalents i 11   i 14   i 12   i 16  
Diluted weighted-average number of common shares outstanding
 i 960   i 964   i 961   i 970  
Anti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents
 i 11   i 11   i 11   i 9  
See Notes to the Condensed Consolidated Financial Statements
2
Table of Contents
UnitedHealth Group
Condensed Consolidated Statements of Comprehensive Income
(Unaudited)
 Three Months Ended June 30,Six Months Ended June 30,
(in millions)2020201920202019
Net earnings$ i 6,696  $ i 3,385  $ i 10,161  $ i 6,942  
Other comprehensive income (loss):
Gross unrealized gains on investment securities during the period
 i 1,120   i 493   i 771   i 1,013  
Income tax effect( i 257) ( i 113) ( i 177) ( i 232) 
Total unrealized gains, net of tax
 i 863   i 380   i 594   i 781  
Gross reclassification adjustment for net realized gains included in net earnings
( i 11) ( i 5) ( i 29) ( i 1) 
Income tax effect i 3   i 1   i 7   i —  
Total reclassification adjustment, net of tax
( i 8) ( i 4) ( i 22) ( i 1) 
Total foreign currency translation (losses) gains
( i 45)  i 109  ( i 1,544)  i 107  
Other comprehensive income (loss) i 810   i 485  ( i 972)  i 887  
Comprehensive income i 7,506   i 3,870   i 9,189   i 7,829  
Comprehensive income attributable to noncontrolling interests( i 59) ( i 92) ( i 142) ( i 182) 
Comprehensive income attributable to UnitedHealth Group common shareholders
$ i 7,447  $ i 3,778  $ i 9,047  $ i 7,647  
See Notes to the Condensed Consolidated Financial Statements
3
Table of Contents

UnitedHealth Group
Condensed Consolidated Statements of Changes in Equity
(Unaudited)
Common StockAdditional Paid-In CapitalRetained EarningsAccumulated Other Comprehensive
Income (Loss)		Nonredeemable Noncontrolling InterestsTotal
Equity
Three months ended June 30,SharesAmountNet Unrealized Gains on InvestmentsForeign Currency Translation (Losses)
Gains
Balance at March 31, 2020
 i 947  $ i 10  $ i —  $ i 62,327  $ i 306  $( i 5,666) $ i 2,886  $ i 59,863  
Net earnings
 i 6,637   i 38   i 6,675  
Other comprehensive income (loss)
 i 855  ( i 45)  i 810  
Issuances of common stock, and related tax effects
 i 3   i —   i 287   i 287  
Share-based compensation
 i 144   i 144  
Common share repurchases i —   i —   i —   i —   i —  
Cash dividends paid on common shares ($1.25 per share)
( i 1,188) ( i 1,188) 
Redeemable noncontrolling interests fair value and other adjustments
( i 43) ( i 43) 
Distribution to nonredeemable noncontrolling interests
( i 33) ( i 33) 
Balance at June 30, 2020
 i 950  $ i 10  $ i 388  $ i 67,776  $ i 1,161  $( i 5,711) $ i 2,891  $ i 66,515  
Balance at March 31, 2019
 i 953  $ i 10  $ i —  $ i 55,472  $ i 140  $( i 3,898) $ i 2,727  $ i 54,451  
Net earnings
 i 3,293   i 54   i 3,347  
Other comprehensive income
 i 376   i 109   i 485  
Issuances of common stock, and related tax effects
 i 1   i —   i 105   i 105  
Share-based compensation
 i 152   i 152  
Common share repurchases( i 6) ( i 1) ( i 124) ( i 1,374) ( i 1,499) 
Cash dividends paid on common shares ($1.08 per share)
( i 1,024) ( i 1,024) 
Redeemable noncontrolling interests fair value and other adjustments
( i 133) ( i 133) 
Acquisition and other adjustments of nonredeemable noncontrolling interests
 i 32   i 32  
Distribution to nonredeemable noncontrolling interests
( i 62) ( i 62) 
Balance at June 30, 2019
 i 948  $ i 9  $ i —  $ i 56,367  $ i 516  $( i 3,789) $ i 2,751  $ i 55,854  
See Notes to the Condensed Consolidated Financial Statements
4
Table of Contents
UnitedHealth Group
Condensed Consolidated Statements of Changes in Equity
(Unaudited)
Common StockAdditional Paid-In CapitalRetained EarningsAccumulated Other Comprehensive
Income (Loss)		Nonredeemable Noncontrolling InterestsTotal
Equity
Six months ended June 30,SharesAmountNet Unrealized Gains (Losses) on InvestmentsForeign Currency Translation (Losses) Gains
Balance at January 1, 2020
 i 948  $ i 9  $ i 7  $ i 61,178  $ i 589  $( i 4,167) $ i 2,820  $ i 60,436  
Adjustment to adopt ASU 2016-13
( i 28) ( i 28) 
Net earnings
 i 10,019   i 97   i 10,116  
Other comprehensive income (loss)
 i 572  ( i 1,544) ( i 972) 
Issuances of common stock, and related tax effects
 i 8   i 1   i 607   i 608  
Share-based compensation
 i 378   i 378  
Common share repurchases( i 6)  i —  ( i 510) ( i 1,181) ( i 1,691) 
Cash dividends paid on common shares ($2.33 per share)
( i 2,212) ( i 2,212) 
Redeemable noncontrolling interests fair value and other adjustments
( i 94) ( i 94) 
Acquisition and other adjustments of nonredeemable noncontrolling interests
 i 50   i 50  
Distribution to nonredeemable noncontrolling interests
( i 76) ( i 76) 
Balance at June 30, 2020
 i 950  $ i 10  $ i 388  $ i 67,776  $ i 1,161  $( i 5,711) $ i 2,891  $ i 66,515  
Balance at January 1, 2019
 i 960  $ i 10  $ i —  $ i 55,846  $( i 264) $( i 3,896) $ i 2,623  $ i 54,319  
Adjustment to adopt ASU 2016-02
( i 13) ( i 5) ( i 18) 
Net earnings
 i 6,760   i 114   i 6,874  
Other comprehensive income
 i 780   i 107   i 887  
Issuances of common stock, and related tax effects
 i 6   i —   i 161   i 161  
Share-based compensation
 i 391   i 391  
Common share repurchases( i 18) ( i 1) ( i 158) ( i 4,342) ( i 4,501) 
Cash dividends paid on common shares ($1.98 per share)
( i 1,884) ( i 1,884) 
Redeemable noncontrolling interests fair value and other adjustments
( i 285) ( i 285) 
Acquisition and other adjustments of nonredeemable noncontrolling interests
( i 109)  i 164   i 55  
Distribution to nonredeemable noncontrolling interests
( i 145) ( i 145) 
Balance at June 30, 2019
 i 948  $ i 9  $ i —  $ i 56,367  $ i 516  $( i 3,789) $ i 2,751  $ i 55,854  
See Notes to the Condensed Consolidated Financial Statements
5
Table of Contents
UnitedHealth Group
Condensed Consolidated Statements of Cash Flows
(Unaudited)
 Six Months Ended June 30,
(in millions)20202019
Operating activities
Net earnings$ i 10,161  $ i 6,942  
Noncash items:
Depreciation and amortization i 1,440   i 1,293  
Deferred income taxes i 114   i 195  
Share-based compensation i 388   i 398  
Other, net i 124  ( i 127) 
Net change in other operating items, net of effects from acquisitions and changes in AARP balances:
Accounts receivable( i 439)  i 2,196  
Other assets( i 3,784) ( i 1,774) 
Medical costs payable( i 2,353)  i 447  
Accounts payable and other liabilities i 7,591  ( i 33) 
Unearned revenues( i 296) ( i 429) 
Cash flows from operating activities i 12,946   i 9,108  
Investing activities
Purchases of investments( i 6,412) ( i 7,649) 
Sales of investments i 3,548   i 2,680  
Maturities of investments i 3,437   i 3,315  
Cash paid for acquisitions, net of cash assumed( i 3,952) ( i 4,751) 
Purchases of property, equipment and capitalized software( i 920) ( i 977) 
Other, net( i 186)  i 504  
Cash flows used for investing activities( i 4,485) ( i 6,878) 
Financing activities
Common share repurchases( i 1,691) ( i 4,501) 
Cash dividends paid( i 2,212) ( i 1,884) 
Proceeds from common stock issuances i 870   i 448  
Repayments of long-term debt i —  ( i 1,250) 
Proceeds from short-term borrowings, net i 351   i 6,924  
Proceeds from issuance of long-term debt i 4,864   i —  
Customer funds administered i 1,263   i 1,435  
Other, net( i 421) ( i 529) 
Cash flows from financing activities i 3,024   i 643  
Effect of exchange rate changes on cash and cash equivalents( i 143)  i 6  
Increase in cash and cash equivalents i 11,342   i 2,879  
Cash and cash equivalents, beginning of period i 10,985   i 10,866  
Cash and cash equivalents, end of period$ i 22,327  $ i 13,745  
See Notes to the Condensed Consolidated Financial Statements
6
Table of Contents
UnitedHealth Group
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
1.  i Basis of Presentation
UnitedHealth Group Incorporated (individually and together with its subsidiaries, “UnitedHealth Group” and “the Company”) is a diversified health care company dedicated to helping people live healthier lives and helping make the health system work better for everyone.
Through its diversified family of businesses, the Company leverages core competencies in data and health information; advanced technology; and clinical expertise. These core competencies are deployed within two distinct, but strategically aligned, business platforms: health benefits operating under UnitedHealthcare and health services operating under Optum.
 i The Company has prepared the Condensed Consolidated Financial Statements according to U.S. Generally Accepted Accounting Principles (GAAP) and has included the accounts of UnitedHealth Group and its subsidiaries. The year-end condensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC), the Company has omitted certain footnote disclosures that would substantially duplicate the disclosures contained in its annual audited Consolidated Financial Statements. Therefore, these Condensed Consolidated Financial Statements should be read together with the Consolidated Financial Statements and the Notes included in Part II, Item 8, “Financial Statements and Supplementary Data” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 as filed with the SEC (2019 10-K). The accompanying Condensed Consolidated Financial Statements include all normal recurring adjustments necessary to present the interim financial statements fairly.
 i 
Use of Estimates
These Condensed Consolidated Financial Statements include certain amounts based on the Company’s best estimates and judgments. The Company’s most significant estimates include medical costs payable and goodwill. Certain of these estimates require the application of complex assumptions and judgments, often because they involve matters that are inherently uncertain and will likely change in subsequent periods. The impact of any change in estimates is included in earnings in the period in which the estimate is adjusted.
 i 
Revenue from Products
For the three and six months ended June 30, 2020, the Company recognized revenue and cost of products sold for retail pharmacy co-payments related to its OptumRx business. Revenue recognized in prior periods related to retail pharmacy transactions excludes the member’s applicable co-payment. There was no impact on earnings from operations, net earnings, earnings per share or total equity.
 i 
Recently Adopted Accounting Standards
In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU) No. 2016-13, “Financial Instruments - Credit Losses (Topic 326)” (ASU 2016-13). ASU 2016-13 requires the use of the current expected credit loss impairment model to develop an estimate of expected credit losses for certain financial assets. ASU 2016-13 also requires expected credit losses on available-for-sale debt securities to be recognized through an allowance for credit losses and revises certain disclosure requirements. The Company adopted ASU 2016-13 on January 1, 2020 using a cumulative effect upon adoption approach. The adoption of ASU 2016-13 was immaterial to the Company’s consolidated balance sheet, results of operations, equity and cash flows.
Under the current expected credit loss impairment model, the Company evaluates an available-for-sale debt security for credit-related impairment by considering the present value of expected cash flows relative to a security’s amortized cost, the extent to which fair value is less than amortized cost, the financial condition and near-term prospects of the issuer and specific events or circumstances that may influence the operations of the issuer. Credit-related impairments are recorded as an allowance, with an offset to investment and other income. Non-credit related impairments are recorded through other comprehensive income. If the Company intends to sell an impaired security, or will likely be required to sell a security before recovery of the entire amortized cost, the entire impairment is included in net earnings.
The Company has determined that there have been no other recently adopted or issued accounting standards that had, or will have, a material impact on its Condensed Consolidated Financial Statements.
7
Table of Contents
2.  i Investments
 i 
A summary of debt securities by major security type is as follows:
(in millions)Amortized
Cost		Gross
Unrealized
Gains		Gross
Unrealized
Losses		Fair
Value
June 30, 2020
Debt securities - available-for-sale:
U.S. government and agency obligations$ i 3,402  $ i 178  $ i —  $ i 3,580  
State and municipal obligations i 5,872   i 330  ( i 3)  i 6,199  
Corporate obligations i 17,324   i 728  ( i 68)  i 17,984  
U.S. agency mortgage-backed securities i 6,005   i 274   i —   i 6,279  
Non-U.S. agency mortgage-backed securities i 1,875   i 83  ( i 14)  i 1,944  
Total debt securities - available-for-sale i 34,478   i 1,593  ( i 85)  i 35,986  
Debt securities - held-to-maturity:
U.S. government and agency obligations i 421   i 8   i —   i 429  
State and municipal obligations i 31   i 2   i —   i 33  
Corporate obligations i 285   i —   i —   i 285  
Total debt securities - held-to-maturity i 737   i 10   i —   i 747  
Total debt securities$ i 35,215  $ i 1,603  $( i 85) $ i 36,733  
December 31, 2019
Debt securities - available-for-sale:
U.S. government and agency obligations$ i 3,502  $ i 55  $( i 4) $ i 3,553  
State and municipal obligations i 5,680   i 251  ( i 5)  i 5,926  
Corporate obligations i 17,910   i 343  ( i 11)  i 18,242  
U.S. agency mortgage-backed securities i 6,425   i 109  ( i 6)  i 6,528  
Non-U.S. agency mortgage-backed securities i 1,811   i 37  ( i 3)  i 1,845  
Total debt securities - available-for-sale i 35,328   i 795  ( i 29)  i 36,094  
Debt securities - held-to-maturity:
U.S. government and agency obligations i 402   i 2   i —   i 404  
State and municipal obligations i 32   i 2   i —   i 34  
Corporate obligations i 538   i —  ( i 1)  i 537  
Total debt securities - held-to-maturity i 972   i 4  ( i 1)  i 975  
Total debt securities$ i 36,300  $ i 799  $( i 30) $ i 37,069  
 / 
The Company held $ i 2.0 billion of equity securities as of June 30, 2020 and December 31, 2019. The Company’s investments in equity securities primarily consist of employee savings plan related investments and shares of Brazilian real denominated fixed-income funds with readily determinable fair values. Additionally, the Company’s investments included $ i 1.4 billion of equity method investments in operating businesses in the health care sector as of June 30, 2020 and December 31, 2019. The allowance for credit losses on held-to-maturity securities at June 30, 2020 was not material.
8
Table of Contents
 i 
The amortized cost and fair value of debt securities as of June 30, 2020, by contractual maturity, were as follows:
Available-for-SaleHeld-to-Maturity
(in millions)Amortized
Cost		Fair
Value		Amortized
Cost		Fair
Value
Due in one year or less$ i 3,414  $ i 3,433  $ i 429  $ i 429  
Due after one year through five years i 10,974   i 11,365   i 255   i 261  
Due after five years through ten years i 8,481   i 9,083   i 31   i 33  
Due after ten years i 3,729   i 3,882   i 22   i 24  
U.S. agency mortgage-backed securities i 6,005   i 6,279  —  —  
Non-U.S. agency mortgage-backed securities i 1,875   i 1,944  —  —  
Total debt securities$ i 34,478  $ i 35,986  $ i 737  $ i 747  
 /  i 
The fair value of available-for-sale debt securities with gross unrealized losses by major security type and length of time that individual securities have been in a continuous unrealized loss position were as follows:
 Less Than 12 Months12 Months or Greater Total
(in millions)Fair
Value		Gross
Unrealized
Losses		Fair
Value		Gross
Unrealized
Losses		Fair
Value		Gross
Unrealized
Losses
June 30, 2020
Debt securities - available-for-sale:
State and municipal obligations$ i 284  $( i 3) $ i —  $ i —  $ i 284  $( i 3) 
Corporate obligations i 1,908  ( i 58)  i 375  ( i 10)  i 2,283  ( i 68) 
Non-U.S. agency mortgage-backed securities
 i 249  ( i 12)  i 42  ( i 2)  i 291  ( i 14) 
Total debt securities - available-for-sale$ i 2,441  $( i 73) $ i 417  $( i 12) $ i 2,858  $( i 85) 
December 31, 2019
Debt securities - available-for-sale:
U.S. government and agency obligations
$ i 616  $( i 4) $ i —  $ i —  $ i 616  $( i 4) 
State and municipal obligations i 440  ( i 5)  i —   i —   i 440  ( i 5) 
Corporate obligations i 1,903  ( i 7)  i 740  ( i 4)  i 2,643  ( i 11) 
U.S. agency mortgage-backed securities i 657  ( i 3)  i 333  ( i 3)  i 990  ( i 6) 
Non-U.S. agency mortgage-backed securities
 i 406  ( i 3)  i —   i —   i 406  ( i 3) 
Total debt securities - available-for-sale$ i 4,022  $( i 22) $ i 1,073  $( i 7) $ i 5,095  $( i 29) 
 / 
The Company’s unrealized losses from debt securities as of June 30, 2020 were generated from approximately  i 3,000 positions out of a total of  i 31,000 positions. The Company believes that it will collect the timely principal and interest due on its debt securities that have an amortized cost in excess of fair value. The unrealized losses were primarily caused by interest rate increases and not by unfavorable changes in the credit quality associated with these securities that impacted our assessment on collectability of principal and interest.  i At each reporting period, the Company evaluates available-for-sale debt securities for any credit-related impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the expected cash flows, the underlying credit quality and credit ratings of the issuers, and the potential economic impacts of COVID-19 on the issuers, noting no significant credit deterioration since purchase. As of June 30, 2020, the Company did not have the intent to sell any of the available-for-sale debt securities in an unrealized loss position. Therefore, the Company believes these losses to be temporary. The allowance for credit losses on available-for-sale debt securities at June 30, 2020 was not material.
9
Table of Contents
3.  i Fair Value
Certain assets and liabilities are measured at fair value in the Condensed Consolidated Financial Statements or have fair values disclosed in the Notes to the Condensed Consolidated Financial Statements. These assets and liabilities are classified into one of three levels of a hierarchy defined by GAAP.
For a description of the methods and assumptions that are used to estimate the fair value and determine the fair value hierarchy classification of each class of financial instrument, see Note 4 of Notes to the Consolidated Financial Statements in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2019 10-K.
 i 
The following table presents a summary of fair value measurements by level and carrying values for items measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets:
(in millions)Quoted Prices
in Active
Markets
(Level 1)		Other
Observable
Inputs
(Level 2)		Unobservable
Inputs
(Level 3)		Total
Fair and Carrying
Value
June 30, 2020
Cash and cash equivalents$ i 22,215  $ i 112  $ i —  $ i 22,327  
Debt securities - available-for-sale:
U.S. government and agency obligations i 3,419   i 161   i —   i 3,580  
State and municipal obligations i —   i 6,199   i —   i 6,199  
Corporate obligations i 63   i 17,654   i 267   i 17,984  
U.S. agency mortgage-backed securities i —   i 6,279   i —   i 6,279  
Non-U.S. agency mortgage-backed securities i —   i 1,944   i —   i 1,944  
Total debt securities - available-for-sale i 3,482   i 32,237   i 267   i 35,986  
Equity securities i 1,530   i 23   i —   i 1,553  
Assets under management  i 1,441   i 1,932   i 44   i 3,417  
Total assets at fair value$ i 28,668  $ i 34,304  $ i 311  $ i 63,283  
Percentage of total assets at fair value45 %54 %1 %100 %
December 31, 2019
Cash and cash equivalents$ i 10,837  $ i 148  $ i —  $ i 10,985  
Debt securities - available-for-sale:
U.S. government and agency obligations i 3,369   i 184   i —   i 3,553  
State and municipal obligations i —   i 5,926   i —   i 5,926  
Corporate obligations i 70   i 17,923   i 249   i 18,242  
U.S. agency mortgage-backed securities i —   i 6,528   i —   i 6,528  
Non-U.S. agency mortgage-backed securities i —   i 1,845   i —   i 1,845  
Total debt securities - available-for-sale i 3,439   i 32,406   i 249   i 36,094  
Equity securities i 1,734   i 22   i —   i 1,756  
Assets under management  i 1,123   i 1,918   i 35   i 3,076  
Total assets at fair value$ i 17,133  $ i 34,494  $ i 284  $ i 51,911  
Percentage of total assets at fair value33 %66 %1 %100 %
 / 
There were no transfers in or out of Level 3 financial assets or liabilities during the six months ended June 30, 2020 or 2019.
10
Table of Contents
 i 
The following table presents a summary of fair value measurements by level and carrying values for certain financial instruments not measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets:
(in millions)Quoted Prices
in Active
Markets
(Level 1)		Other
Observable
Inputs
(Level 2)		Unobservable
Inputs
(Level 3)		Total
Fair
Value		Total Carrying Value
June 30, 2020
Debt securities - held-to-maturity$ i 566  $ i 96  $ i 85  $ i 747  $ i 737  
Long-term debt and other financing obligations$ i —  $ i 53,119  $ i —  $ i 53,119  $ i 45,284  
December 31, 2019
Debt securities - held-to-maturity$ i 541  $ i 181  $ i 253  $ i 975  $ i 972  
Long-term debt and other financing obligations$ i —  $ i 45,078  $ i —  $ i 45,078  $ i 40,278  
 / 
Nonfinancial assets and liabilities or financial assets and liabilities that are measured at fair value on a nonrecurring basis are subject to fair value adjustments only in certain circumstances, such as when the Company records an impairment. There were no significant fair value adjustments for these assets and liabilities recorded during either the six months ended June 30, 2020 or 2019.
4.  i Medical Costs Payable
 i 
The following table shows the components of the change in medical costs payable for the six months ended June 30:
(in millions)20202019
Medical costs payable, beginning of period$ i 21,690  $ i 19,891  
Acquisitions i 41   i 522  
Reported medical costs:
Current year i 76,338   i 78,523  
Prior years( i 660) ( i 400) 
Total reported medical costs i 75,678   i 78,123  
Medical payments:
Payments for current year
( i 59,482) ( i 60,707) 
Payments for prior years( i 18,727) ( i 16,922) 
Total medical payments( i 78,209) ( i 77,629) 
Medical costs payable, end of period$ i 19,200  $ i 20,907  
 / 
For the six months ended June 30, 2020, prior years medical cost reserve development was primarily driven by lower than expected health system utilization. For the six months ended June 30, 2019, the prior years medical cost reserve development included no individual factors that were significant. Medical costs payable included reserves for claims incurred by insured customers but not yet reported to the Company of $ i 13.7 billion and $ i 13.8 billion at June 30, 2020 and December 31, 2019, respectively.
11
Table of Contents
5.  i  i  i  i  i Short-Term Borrowings and Long-Term Debt  /  /  /  / 
 i 
Short-term borrowings and senior unsecured long-term debt consisted of the following:
 June 30, 2020December 31, 2019
(in millions, except percentages)Par ValueCarrying ValueFair ValuePar ValueCarrying ValueFair Value
Commercial paper$ i 773  $ i 773  $ i 773  $ i 400  $ i 400  $ i 400  
2.700% notes due July 2020  i 1,500   i 1,500   i 1,501   i 1,500   i 1,499   i 1,506  
Floating rate notes due October 2020  i 300   i 300   i 300   i 300   i 300   i 300  
3.875% notes due October 2020  i 450   i 452   i 451   i 450   i 450   i 455  
1.950% notes due October 2020  i 900   i 900   i 904   i 900   i 899   i 900  
4.700% notes due February 2021  i 400   i 405   i 406   i 400   i 403   i 410  
2.125% notes due March 2021
 i 750   i 749   i 759   i 750   i 749   i 753  
Floating rate notes due June 2021
 i 350   i 350   i 350   i 350   i 349   i 350  
3.150% notes due June 2021
 i 400   i 399   i 411   i 400   i 399   i 407  
3.375% notes due November 2021
 i 500   i 511   i 517   i 500   i 501   i 512  
2.875% notes due December 2021
 i 750   i 768   i 778   i 750   i 753   i 765  
2.875% notes due March 2022
 i 1,100   i 1,117   i 1,139   i 1,100   i 1,087   i 1,121  
3.350% notes due July 2022  i 1,000   i 998   i 1,061   i 1,000   i 998   i 1,036  
2.375% notes due October 2022  i 900   i 897   i 942   i 900   i 896   i 911  
0.000% notes due November 2022
 i 15   i 13   i 14   i 15   i 13   i 14  
2.750% notes due February 2023  i 625   i 648   i 659   i 625   i 624   i 638  
2.875% notes due March 2023  i 750   i 798   i 799   i 750   i 770   i 770  
3.500% notes due June 2023  i 750   i 748   i 817   i 750   i 747   i 786  
3.500% notes due February 2024 i 750   i 746   i 825   i 750   i 746   i 792  
2.375% notes due August 2024 i 750   i 747   i 801   i 750   i 747   i 760  
3.750% notes due July 2025  i 2,000   i 1,991   i 2,279   i 2,000   i 1,990   i 2,161  
3.700% notes due December 2025 i 300   i 298   i 344   i 300   i 298   i 325  
1.250% notes due January 2026 i 500   i 496   i 509   i —   i —   i —  
3.100% notes due March 2026 i 1,000   i 996   i 1,116   i 1,000   i 996   i 1,048  
3.450% notes due January 2027 i 750   i 746   i 855   i 750   i 746   i 804  
3.375% notes due April 2027 i 625   i 620   i 712   i 625   i 620   i 667  
2.950% notes due October 2027 i 950   i 940   i 1,060   i 950   i 939   i 988  
3.850% notes due June 2028 i 1,150   i 1,143   i 1,360   i 1,150   i 1,142   i 1,269  
3.875% notes due December 2028 i 850   i 843   i 1,017   i 850   i 843   i 941  
2.875% notes due August 2029 i 1,000   i 1,111   i 1,116   i 1,000   i 993   i 1,029  
2.000% notes due May 2030 i 1,250   i 1,233   i 1,309   i —   i —   i —  
4.625% notes due July 2035  i 1,000   i 992   i 1,308   i 1,000   i 992   i 1,215  
5.800% notes due March 2036 i 850   i 838   i 1,202   i 850   i 838   i 1,129  
6.500% notes due June 2037 i 500   i 492   i 761   i 500   i 492   i 712  
6.625% notes due November 2037 i 650   i 641   i 994   i 650   i 641   i 940  
6.875% notes due February 2038 i 1,100   i 1,077   i 1,713   i 1,100   i 1,076   i 1,631  
3.500% notes due August 2039 i 1,250   i 1,241   i 1,454   i 1,250   i 1,241   i 1,313  
2.750% notes due May 2040 i 1,000   i 963   i 1,071   i —   i —   i —  
5.700% notes due October 2040 i 300   i 296   i 438   i 300   i 296   i 396  
5.950% notes due February 2041 i 350   i 345   i 521   i 350   i 345   i 475  
4.625% notes due November 2041 i 600   i 589   i 787   i 600   i 589   i 716  
4.375% notes due March 2042 i 502   i 484   i 642   i 502   i 484   i 580  
3.950% notes due October 2042 i 625   i 608   i 749   i 625   i 607   i 688  
4.250% notes due March 2043 i 750   i 735   i 938   i 750   i 735   i 856  
4.750% notes due July 2045  i 2,000   i 1,973   i 2,694   i 2,000   i 1,973   i 2,463  
4.200% notes due January 2047 i 750   i 738   i 951   i 750   i 738   i 861  
4.250% notes due April 2047 i 725   i 717   i 931   i 725   i 717   i 839  
3.750% notes due October 2047 i 950   i 934   i 1,134   i 950   i 934   i 1,023  
4.250% notes due June 2048 i 1,350   i 1,330   i 1,726   i 1,350   i 1,330   i 1,569  
4.450% notes due December 2048 i 1,100   i 1,086   i 1,440   i 1,100   i 1,086   i 1,316  
3.700% notes due August 2049 i 1,250   i 1,235   i 1,479   i 1,250   i 1,235   i 1,344  
2.900% notes due May 2050 i 1,250   i 1,208   i 1,320   i —   i —   i —  
3.875% notes due August 2059 i 1,250   i 1,228   i 1,531   i 1,250   i 1,228   i 1,350  
3.125% notes due May 2060 i 1,000   i 967   i 1,072   i —   i —   i —  
Total short-term borrowings and long-term debt$ i 45,190  $ i 44,953  $ i 52,740  $ i 39,817  $ i 39,474  $ i 44,234  
 / 

12
Table of Contents
The Company’s long-term debt obligations also included $ i 1.1 billion and $ i 1.2 billion of other financing obligations, of which $ i 328 million and $ i 322 million were classified as current as of June 30, 2020 and December 31, 2019, respectively.
Commercial Paper and Bank Credit Facilities
Commercial paper consists of short-duration, senior unsecured debt privately placed on a discount basis through broker-dealers. As of June 30, 2020, the Company’s outstanding commercial paper had a weighted average annual interest rate of  i 0.3%.
The Company has $ i 4.4 billion five-year, $ i 4.4 billion three-year and $ i 3.8 billion 364-day revolving bank credit facilities with 25 banks, which mature in December 2024, December 2022 and December 2020, respectively. These facilities provide liquidity support for the Company’s commercial paper program and are available for general corporate purposes. As of June 30, 2020, no amounts had been drawn on any of the bank credit facilities. The annual interest rates, which are variable based on term, are calculated based on the London Interbank Offered Rate (LIBOR) plus a credit spread based on the Company’s senior unsecured credit ratings. If amounts had been drawn on the bank credit facilities as of June 30, 2020, annual interest rates would have ranged from  i 0.8% to  i 1.1%.
Debt Covenants
The Company’s bank credit facilities contain various covenants, including covenants requiring the Company to maintain a defined debt to debt-plus-shareholders’ equity ratio of not more than 60%. The Company was in compliance with its debt covenants as of June 30, 2020.
6.  i Dividends
In June 2020, the Company’s Board of Directors increased the Company’s quarterly cash dividend to shareholders to an annual rate of $5.00 compared to $4.32 per share, which the Company had paid since June 2019. Declaration and payment of future quarterly dividends is at the discretion of the Board and may be adjusted as business needs or market conditions change.
 i 
The following table provides details of the Company’s 2020 dividend payments:
Payment DateAmount per ShareTotal Amount Paid
(in millions)
March 24$ i 1.08$ i 1,024  
June 30$ i 1.25 i 1,188  
 / 
7.  i Commitments and Contingencies
Legal Matters
Because of the nature of its businesses, the Company is frequently made party to a variety of legal actions and regulatory inquiries, including class actions and suits brought by members, care providers, consumer advocacy organizations, customers and regulators, relating to the Company’s businesses, including management and administration of health benefit plans and other services. These matters include medical malpractice, employment, intellectual property, antitrust, privacy and contract claims and claims related to health care benefits coverage and other business practices.
The Company records liabilities for its estimates of probable costs resulting from these matters where appropriate. Estimates of costs resulting from legal and regulatory matters involving the Company are inherently difficult to predict, particularly where the matters: involve indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present novel legal theories or represent a shift in regulatory policy; involve a large number of claimants or regulatory bodies; are in the early stages of the proceedings; or could result in a change in business practices. Accordingly, the Company is often unable to estimate the losses or ranges of losses for those matters where there is a reasonable possibility or it is probable that a loss may be incurred.
Government Investigations, Audits and Reviews
The Company has been involved or is currently involved in various governmental investigations, audits and reviews. These include routine, regular and special investigations, audits and reviews by the Centers for Medicare and Medicaid Services (CMS), state insurance and health and welfare departments, state attorneys general, the Office of the Inspector General, the Office of Personnel Management, the Office of Civil Rights, the Government Accountability Office, the Federal Trade Commission, U.S. Congressional committees, the U.S. Department of Justice, the SEC, the Internal Revenue Service, the U.S. Drug Enforcement Administration, the U.S. Department of Labor, the Federal Deposit Insurance Corporation, the Defense Contract Audit Agency and other governmental authorities. Similarly, our international businesses are also subject to investigations, audits and reviews by applicable foreign governments, including South American and other non-U.S.
13
Table of Contents
governmental authorities. Certain of the Company’s businesses have been reviewed or are currently under review, including for, among other matters, compliance with coding and other requirements under the Medicare risk-adjustment model. CMS has selected certain of the Company’s local plans for risk adjustment data validation (RADV) audits to validate the coding practices of and supporting documentation maintained by health care providers and such audits may result in retrospective adjustments to payments made to the Company’s health plans.
On February 14, 2017, the Department of Justice (DOJ) announced its decision to pursue certain claims within a lawsuit initially asserted against the Company and filed under seal by a whistleblower in 2011. The whistleblower’s complaint, which was unsealed on February 15, 2017, alleges that the Company made improper risk adjustment submissions and violated the False Claims Act. On February 12, 2018, the court granted in part and denied in part the Company’s motion to dismiss. In May 2018, DOJ moved to dismiss the Company’s counterclaims, which were filed in March 2018, and moved for partial summary judgment. In March 2019, the court denied the government’s motion for partial summary judgment and dismissed the Company’s counterclaims without prejudice. The Company cannot reasonably estimate the outcome that may result from this matter given its procedural status.
8.  i Segment Financial Information
The Company’s  i four reportable segments are UnitedHealthcare, OptumHealth, OptumInsight and OptumRx. For more information on the Company’s segments see Part I, Item I, “Business” and Note 14 of Notes to the Consolidated Financial Statements in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2019 10-K.
 i 
The following tables present reportable segment financial information:
  Optum  
(in millions)UnitedHealthcareOptumHealthOptumInsightOptumRxOptum EliminationsOptumCorporate and
Eliminations		Consolidated
Three Months Ended June 30, 2020
Revenues - unaffiliated customers:
Premiums$ i 47,039  $ i 2,355  $ i —  $ i —  $ i —  $ i 2,355  $ i —  $ i 49,394  
Products i —   i 7   i 27   i 8,213   i —   i 8,247   i —   i 8,247  
Services i 1,895   i 1,225   i 764   i 272   i —   i 2,261   i —   i 4,156  
Total revenues - unaffiliated customers
 i 48,934   i 3,587   i 791   i 8,485   i —   i 12,863   i —   i 61,797  
Total revenues - affiliated customers
 i —   i 5,423   i 1,823   i 12,865  ( i 447)  i 19,664  ( i 19,664)  i —  
Investment and other income
 i 173   i 129   i 18   i 21   i —   i 168   i —   i 341  
Total revenues$ i 49,107  $ i 9,139  $ i 2,632  $ i 21,371  $( i 447) $ i 32,695  $( i 19,664) $ i 62,138  
Earnings from operations$ i 7,007  $ i 841  $ i 561  $ i 832  $ i —  $ i 2,234  $ i —  $ i 9,241  
Interest expense i —   i —   i —   i —   i —   i —  ( i 430) ( i 430) 
Earnings before income taxes
$ i 7,007  $ i 841  $ i 561  $ i 832  $ i —  $ i 2,234  $( i 430) $ i 8,811  
Three Months Ended June 30, 2019
Revenues - unaffiliated customers:
Premiums$ i 46,030  $ i 1,134  $ i —  $ i —  $ i —  $ i 1,134  $ i —  $ i 47,164  
Products i —   i 9   i 22   i 8,322   i —   i 8,353   i —   i 8,353  
Services i 2,188   i 1,370   i 790   i 148   i —   i 2,308   i —   i 4,496  
Total revenues - unaffiliated customers
 i 48,218   i 2,513   i 812   i 8,470   i —   i 11,795   i —   i 60,013  
Total revenues - affiliated customers
 i —   i 4,449   i 1,521   i 10,439  ( i 381)  i 16,028  ( i 16,028)  i —  
Investment and other income
 i 376   i 186   i 6   i 14   i —   i 206   i —   i 582  
Total revenues$ i 48,594  $ i 7,148  $ i 2,339  $ i 18,923  $( i 381) $ i 28,029  $( i 16,028) $ i 60,595  
Earnings from operations$ i 2,642  $ i 688  $ i 525  $ i 889  $ i —  $ i 2,102  $ i —  $ i 4,744  
Interest expense i —   i —   i —   i —   i —   i —  ( i 418) ( i 418) 
Earnings before income taxes
$ i 2,642  $ i 688  $ i 525  $ i 889  $ i —  $ i 2,102  $( i 418) $ i 4,326  
 / 
14
Table of Contents
Optum
(in millions)UnitedHealthcareOptumHealthOptumInsightOptumRxOptum EliminationsOptumCorporate and EliminationsConsolidated
Six Months Ended June 30, 2020
Revenues - unaffiliated customers:
Premiums$ i 95,632  $ i 4,402  $ i —  $ i —  $ i —  $ i 4,402  $ i —  $ i 100,034  
Products i —   i 16   i 56   i 16,606   i —   i 16,678   i —   i 16,678  
Services i 4,173   i 2,773   i 1,655   i 540   i —   i 4,968   i —   i 9,141  
Total revenues - unaffiliated customers i 99,805   i 7,191   i 1,711   i 17,146   i —   i 26,048   i —   i 125,853  
Total revenues - affiliated customers i —   i 10,875   i 3,385   i 25,741  ( i 851)  i 39,150  ( i 39,150)  i —  
Investment and other income i 370   i 265   i 30   i 41   i —   i 336   i —   i 706  
Total revenues$ i 100,175  $ i 18,331  $ i 5,126  $ i 42,928  $( i 851) $ i 65,534  $( i 39,150) $ i 126,559  
Earnings from operations$ i 9,895  $ i 1,553  $ i 1,097  $ i 1,692  $ i —  $ i 4,342  $ i —  $ i 14,237  
Interest expense i —   i —   i —   i —   i —   i —  ( i 867) ( i 867) 
Earnings before income taxes$ i 9,895  $ i 1,553  $ i 1,097  $ i 1,692  $ i —  $ i 4,342  $( i 867) $ i 13,370  
Six Months Ended June 30, 2019
Revenues - unaffiliated customers:
Premiums$ i 92,531  $ i 2,146  $ i —  $ i —  $ i —  $ i 2,146  $ i —  $ i 94,677  
Products i —   i 17   i 45   i 16,363   i —   i 16,425   i —   i 16,425  
Services i 4,329   i 2,644   i 1,544   i 297   i —   i 4,485   i —   i 8,814  
Total revenues - unaffiliated customers i 96,860   i 4,807   i 1,589   i 16,660   i —   i 23,056   i —   i 119,916  
Total revenues - affiliated customers i —   i 8,736   i 2,928   i 20,052  ( i 740)  i 30,976  ( i 30,976)  i —  
Investment and other income i 630   i 318   i 11   i 28   i —   i 357   i —   i 987  
Total revenues$ i 97,490  $ i 13,861  $ i 4,528  $ i 36,740  $( i 740) $ i 54,389  $( i 30,976) $ i 120,903  
Earnings from operations$ i 5,596  $ i 1,314  $ i 957  $ i 1,709  $ i —  $ i 3,980  $ i —  $ i 9,576  
Interest expense i —   i —   i —   i —   i —   i —  ( i 818) ( i 818) 
Earnings before income taxes$ i 5,596  $ i 1,314  $ i 957  $ i 1,709  $ i —  $ i 3,980  $( i 818) $ i 8,758  
15
Table of Contents
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion should be read together with the accompanying Condensed Consolidated Financial Statements and Notes and with our 2019 10-K, including the Consolidated Financial Statements and Notes in Part II, Item 8, “Financial Statements and Supplementary Data” in that report. Unless the context indicates otherwise, references to the terms “UnitedHealth Group,” “we,” “our” or “us” used throughout this Management’s Discussion and Analysis of Financial Condition and Results of Operations refer to UnitedHealth Group Incorporated and its consolidated subsidiaries.
Readers are cautioned that the statements, estimates, projections or outlook contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations, including discussions regarding financial prospects, economic conditions, trends and uncertainties contained in this Item 2, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve risks and uncertainties that may cause our actual results to differ materially from the results discussed or implied in the forward-looking statements. A description of some of the risks and uncertainties is set forth in Part I, Item 1A, “Risk Factors” in our 2019 10-K and in the discussion below.
EXECUTIVE OVERVIEW
General
UnitedHealth Group is a diversified health care company dedicated to helping people live healthier lives and helping make the health system work better for everyone. Through our diversified family of businesses, we leverage core competencies in data and health information, advanced technology, and clinical expertise, focused on improving health outcomes, lowering health care costs and creating a better experience for patients, their caregivers and physicians. These core competencies are deployed within our two distinct, but strategically aligned, business platforms: health benefits operating under UnitedHealthcare and health services operating under Optum.
Further information on our business is presented in Part I, Item 1, “Business” and Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2019 10-K and additional information on our segments can be found in this Item 2 and in Note 8 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.
COVID-19 Trends and Uncertainties
The COVID-19 pandemic continues to evolve and the ultimate impact on our business, results of operations, financial condition and cash flows remains uncertain and difficult to predict. During the quarter, the global health system experienced unprecedented levels of care deferral, which meaningfully impacted all of our businesses. As the pandemic advanced, access to and demand for care was most constrained from mid-March through April, began to recover in May and approached more typical levels by the end of the second quarter. The temporary deferral of care may cause care patterns to moderately exceed normal baselines in the second half of this year as utilization of health system capacity continues to increase. Health system capacity may be subject to possible increased volatility due to the pandemic from time to time. Specific trends and uncertainties related to our two business platforms are as follows:

UnitedHealthcare. We have expanded benefit coverage in areas such as COVID-19 testing and treatment, telemedicine, and pharmacy benefits; provided customers assistance in the form of co-pay waivers and premium forgiveness; offered additional enrollment opportunities to those who previously declined employer-sponsored offerings; extended certain premium payment terms for customers experiencing financial hardship; simplified administrative practices; and accelerated payments to care providers, all with the aim of assisting our customers, providers and members in addressing the COVID-19 crisis. Temporary care deferrals significantly impacted UnitedHealthcare’s results of operations for the three-months ended June 30, 2020, contributing to significantly lower medical costs and higher operating earnings than previous periods. The impact of care disruption has been, and will continue to be offset by factors such as COVID-19 related treatment and testing, potential future vaccines and the financial assistance we continue to provide our customers. As health system capacity continues to approach normal levels, consumer demand for care, potentially even higher acuity care, is expected to result in increased future medical costs. Disrupted care patterns, as a result of the pandemic, may temporarily affect the ability to obtain complete member health status information, impacting future revenue in businesses that utilize risk adjustment methodologies. Depending on the future pacing and intensity of the virus, as well as the duration of policies and initiatives to address COVID-19, the ultimate impact is uncertain.


16
Table of Contents
Optum. The temporary deferral of care also meaningfully impacted the Optum businesses for the three-months ended June 30, 2020. For example, our fee-for-service care delivery business, such as traditional procedure work at our ambulatory surgery centers, was negatively impacted, while our risk-based care delivery business performance reflected lower demand for care. Our OptumInsight and OptumRx volume-based businesses were negatively impacted by the lower level of care encounters which took place, contributing to lower managed services and prescription volume. As the health system continues to return nearer to normal seasonally adjusted levels of care, we have seen business activity approach more normal levels. COVID-19 will also continue to influence customer and consumer behavior, both during and after the pandemic, which could impact how care is delivered and the manner in which consumers wish to receive their prescription drugs or infusion services. The impact of COVID-19 on our care provider and payer clients could impact the volume and types of services that Optum provides, as well as the pacing of potential new business opportunities. As a result of the dynamic situation and broad-reaching impact to the health system, the ultimate impact of COVID-19 is uncertain.

Business Trends
Our businesses participate in the United States, South American and certain other international health markets. Overall spending on health care is impacted by inflation; utilization; medical technology and pharmaceutical advancement; regulatory requirements; demographic trends in the population; and national interest in health and well-being. The rate of market growth may be affected by a variety of factors, including macro-economic conditions, such as the economic impact of COVID-19, and regulatory changes, which could impact our results of operations, including our continued efforts to control health care costs.
Pricing Trends. To price our health care benefit products, we start with our view of expected future costs, including any potential impacts from COVID-19 and the Health Insurance Tax. We frequently evaluate and adjust our approach in each of the local markets we serve, considering all relevant factors, such as product positioning, price competitiveness and environmental, competitive, legislative and regulatory considerations, including minimum medical loss ratio (MLR) thresholds. We will continue seeking to balance growth and profitability across all these dimensions.
The commercial risk market remains highly competitive in both the small group and large group segments. We expect broad-based competition to continue as the industry adapts to individual and employer needs amid reform changes. Pricing for contracts that cover some portion of calendar year 2021 will reflect the permanent repeal of the Health Insurance Tax.
Government programs in the public and senior sector tend to receive lower rates of increase than the commercial market due to governmental budget pressures and lower cost trends.
Medical Cost Trends. Our medical cost trends primarily relate to changes in unit costs, health system utilization and prescription drug costs. We endeavor to mitigate those increases by engaging physicians and consumers with information and helping them make clinically sound choices, with the objective of helping them achieve high quality, affordable care. The uncertain impact of COVID-19 may impact our ability to estimate medical costs payable, which could result in increased variability to medical cost reserve development in future periods. As a result of higher than expected care deferrals, favorable reserve development of $1.4 billion occurred in the second quarter.
Regulatory Trends and Uncertainties
Following is a summary of management’s view of regulatory trends and uncertainties. For additional information regarding regulatory trends and uncertainties, see Part I, Item 1 “Business - Government Regulation,” Part 1, Item 1A, “Risk Factors,” Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2019 10-K and “Risk Factors” in Part II, Item 1A of this report.
Medicare Advantage Rates. Final 2021 Medicare Advantage rates resulted in an increase in industry base rates of approximately 1.7%, short of the industry forward medical cost trend, creating continued pressure in the Medicare Advantage program.
Affordable Care Act (ACA) Tax. After a moratorium in 2019, the industry-wide amount of the Health Insurance Tax for 2020, which is primarily borne by customers, is $15.5 billion, with our portion being approximately $3.0 billion. The return of the tax impacts year-over-year comparability of our financial statements, including revenues, operating costs, medical care ratio (MCR), operating cost ratio, effective tax rate and cash flows from operations. The ACA Tax was permanently repealed by Congress, effective January 1, 2021.
17
Table of Contents

SELECTED OPERATING PERFORMANCE AND OTHER SIGNIFICANT ITEMS
The following summarizes select second quarter 2020 year-over-year operating comparisons to second quarter 2019, which were significantly impacted by the effects of COVID-19 on the health system.
•Consolidated revenues grew 3%, UnitedHealthcare revenues grew 1% and Optum revenues grew 17%.
•UnitedHealthcare served 425,000 fewer people domestically primarily due to increased unemployment and expected attrition in commercial group benefits and the proactive withdrawal from a Medicaid market.
•Consolidated earnings from operations increased, primarily due to temporary care deferrals caused by COVID-19, including increases at UnitedHealthcare and Optum.
•Diluted earnings per common share increased to $6.91.
•Cash flows from operations for the six months ended June 30, 2020 were $12.9 billion.
•Return on equity was 44.0%.
RESULTS SUMMARY
The following table summarizes our consolidated results of operations and other financial information:
(in millions, except percentages and per share data)Three Months Ended June 30,Increase/(Decrease)Six Months Ended
June 30,		Increase/(Decrease)
202020192020 vs. 2019202020192020 vs. 2019
Revenues:
Premiums$49,394  $47,164  $2,230  5 %$100,034  $94,677  $5,357  6 %
Products8,247  8,353  (106) (1) 16,678  16,425  253  2  
Services4,156  4,496  (340) (8) 9,141  8,814  327  4  
Investment and other income
341  582  (241) (41) 706  987  (281) (28) 
Total revenues62,138  60,595  1,543  3  126,559  120,903  5,656  5  
Operating costs:
Medical costs34,678  39,184  (4,506) (11) 75,678  78,123  (2,445) (3) 
Operating costs10,001  8,415  1,586  19  20,016  16,932  3,084  18  
Cost of products sold7,501  7,598  (97) (1) 15,188  14,979  209  1  
Depreciation and amortization
717  654  63  10  1,440  1,293  147  11  
Total operating costs52,897  55,851  (2,954) (5) 112,322  111,327  995  1  
Earnings from operations9,241  4,744  4,497  95  14,237  9,576  4,661  49  
Interest expense(430) (418) (12) 3  (867) (818) (49) 6  
Earnings before income taxes8,811  4,326  4,485  104  13,370  8,758  4,612  53  
Provision for income taxes(2,115) (941) (1,174) 125  (3,209) (1,816) (1,393) 77  
Net earnings6,696  3,385  3,311  98  10,161  6,942  3,219  46  
Earnings attributable to noncontrolling interests
(59) (92) 33  (36) (142) (182) 40  (22) 
Net earnings attributable to UnitedHealth Group common shareholders
$6,637  $3,293  $3,344  102 %$10,019  $6,760  $3,259  48 %
Diluted earnings per share attributable to UnitedHealth Group common shareholders
$6.91  $3.42  $3.49  102 %$10.43  $6.97  $3.46  50 %
Medical care ratio (a)70.2 %83.1 %(12.9)%75.7 %82.5 %(6.8)%
Operating cost ratio16.1  13.9  2.2  15.8  14.0  1.8  
Operating margin14.9  7.8  7.1  11.2  7.9  3.3  
Tax rate24.0  21.8  2.2  24.0  20.7  3.3  
Net earnings margin (b)10.7  5.4  5.3  7.9  5.6  2.3  
Return on equity (c)44.0 %25.1 %18.9 %33.7 %25.9 %7.8 %
(a)Medical care ratio is calculated as medical costs divided by premium revenue.
(b)Net earnings margin attributable to UnitedHealth Group shareholders.
(c)Return on equity is calculated as annualized net earnings attributable to UnitedHealth Group common shareholders divided by average shareholders’ equity. Average shareholders’ equity is calculated using the shareholders’ equity balance at the end of the preceding year and the shareholders’ equity balances at the end of each of the quarters in the year presented.
18
Table of Contents
2020 RESULTS OF OPERATIONS COMPARED TO 2019 RESULTS OF OPERATIONS
Consolidated Financial Results
Revenue
The increases in revenue were primarily driven by the increase in the number of individuals served through Medicare Advantage; pricing trends; and acquisition and organic growth across the Optum business, primarily due to expansion in pharmacy care services and care delivery. The increases were partially offset by decreased individuals served through our Medicaid, commercial and Global benefits businesses; decreases in our fee-for-service care delivery and other volume-based businesses, primarily as a result of the impacts of COVID-19 on the economy and health system; and certain customer assistance programs.
Medical Costs and MCR
Medical costs decreased as a result of the temporary deferral of care due to COVID-19 and decreased people served in Medicaid, commercial and Global, partially offset by growth in people served through Medicare Advantage and medical cost trends. The MCR decreased primarily due to the temporary deferral of care and the revenue effects of the return of the Health Insurance Tax.
Operating Cost Ratio
The operating cost ratio increased primarily due to the impact of the return of the Health Insurance Tax and the Company’s COVID-19 response efforts.
Income Tax Rate
Our effective tax rate increased primarily due to the impact of the return of the nondeductible Health Insurance Tax.
19
Table of Contents
Reportable Segments
See Note 8 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report for more information on our segments. We utilize various metrics to evaluate and manage our reportable segments, including individuals served by UnitedHealthcare by major market segment and funding arrangement, people served by OptumHealth and adjusted scripts for OptumRx. These metrics are the main drivers of revenue, earnings and cash flows at each business. The metrics also allow management and investors to evaluate and understand business mix, customer penetration and pricing trends when comparing the metrics to revenue by segment.
The following table presents a summary of the reportable segment financial information:
 Three Months Ended June 30,Increase/(Decrease)Six Months Ended
June 30,		Increase/(Decrease)
(in millions, except percentages)202020192020 vs. 2019202020192020 vs. 2019
Revenues
UnitedHealthcare$49,107  $48,594  $513  1 %$100,175  $97,490  $2,685  3 %
OptumHealth9,139  7,148  1,991  28  18,331  13,861  4,470  32  
OptumInsight2,632  2,339  293  13  5,126  4,528  598  13  
OptumRx21,371  18,923  2,448  13  42,928  36,740  6,188  17  
Optum eliminations(447) (381) (66) 17  (851) (740) (111) 15  
Optum
32,695  28,029  4,666  17  65,534  54,389  11,145  20  
Eliminations(19,664) (16,028) (3,636) 23  (39,150) (30,976) (8,174) 26  
Consolidated revenues$62,138  $60,595  $1,543  3 %$126,559  $120,903  $5,656  5 %
Earnings from operations
UnitedHealthcare$7,007  $2,642  $4,365  165 %$9,895  $5,596  $4,299  77 %
OptumHealth841  688  153  22  1,553  1,314  239  18  
OptumInsight561  525  36  7  1,097  957  140  15  
OptumRx832  889  (57) (6) 1,692  1,709  (17) (1) 
Optum
2,234  2,102  132  6  4,342  3,980  362  9  
Consolidated earnings from operations
$9,241  $4,744  $4,497  95 %$14,237  $9,576  $4,661  49 %
Operating margin
UnitedHealthcare14.3 %5.4 %8.9 %9.9 %5.7 %4.2 %
OptumHealth9.2  9.6  (0.4) 8.5  9.5  (1.0) 
OptumInsight21.3  22.4  (1.1) 21.4  21.1  0.3  
OptumRx3.9  4.7  (0.8) 3.9  4.7  (0.8) 
Optum
6.8  7.5  (0.7) 6.6  7.3  (0.7) 
Consolidated operating margin14.9 %7.8 %7.1 %11.2 %7.9 %3.3 %
UnitedHealthcare
The following table summarizes UnitedHealthcare revenues by business:
 Three Months Ended June 30,Increase/(Decrease)Six Months Ended June 30,Increase/(Decrease)
(in millions, except percentages)202020192020 vs. 2019202020192020 vs. 2019
UnitedHealthcare Employer & Individual
$12,963  $14,032  $(1,069) (8)%$27,243  $28,116  $(873) (3)%
UnitedHealthcare Medicare & Retirement
22,855  20,855  2,000  10  46,007  41,951  4,056  10  
UnitedHealthcare Community & State
11,523  11,186  337  3  22,976  22,368  608  3  
UnitedHealthcare Global1,766  2,521  (755) (30) 3,949  5,055  (1,106) (22) 
Total UnitedHealthcare revenues$49,107  $48,594  $513  1 %$100,175  $97,490  $2,685  3 %
20
Table of Contents
The following table summarizes the number of individuals served by our UnitedHealthcare businesses, by major market segment and funding arrangement:
June 30,Increase/(Decrease)
(in thousands, except percentages)202020192020 vs. 2019
Commercial:
Risk-based8,065  8,325  (260) (3)%
Fee-based18,705  19,090  (385) (2) 
Total commercial26,770  27,415  (645) (2) 
Medicare Advantage5,605  5,190  415  8  
Medicaid6,210  6,360  (150) (2) 
Medicare Supplement (Standardized)4,450  4,495  (45) (1) 
Total public and senior16,265  16,045  220  1  
Total UnitedHealthcare - domestic medical43,035  43,460  (425) (1) 
Global5,365  6,070  (705) (12) 
Total UnitedHealthcare - medical48,400  49,530  (1,130) (2)%
Supplemental Data:
Medicare Part D stand-alone4,120  4,430  (310) (7)%
Fee-based and risk-based commercial business decreased primarily due to increased unemployment and expected attrition. Medicare Advantage increased due to growth in people served through individual Medicare Advantage plans. The decrease in people served through Medicaid was primarily driven by the proactive withdrawal from a market as well as by states managing eligibility, partially offset by increases in Dual Special Needs Plans and states easing redetermination requirements. The decrease in people served by UnitedHealthcare Global is a result of our continued affordability efforts, underwriting discipline and increased unemployment.
UnitedHealthcare’s revenue increased due to growth in the number of individuals served through Medicare Advantage, a greater mix of people with higher acuity needs and the return of the Health Insurance Tax, partially offset by a decrease in the number of individuals served through the commercial, Medicaid and Global businesses and foreign currency impacts. Earnings from operations increased due to the deferral of care caused by COVID-19 on the health system and the factors impacting revenue, partially offset by the return of the Health Insurance Tax, COVID-19 treatment and testing costs and customer assistance programs.
Optum
Total revenues increased as each segment reported revenue growth. Earnings from operations increased due to growth at OptumHealth and OptumInsight, partially offset by decreased earnings from operations at OptumRx.
The results by segment were as follows:
OptumHealth
Revenue and earnings at OptumHealth increased primarily due to acquisitions and organic growth in risk-based care delivery, partially offset by reduced care volumes in fee-for-service arrangements as a result of COVID-19. Earnings from operations also increased at our risk-based business due to the deferral of care caused by COVID-19. OptumHealth served approximately 97 million people as of June 30, 2020 compared to 95 million people as of June 30, 2019.
OptumInsight
Revenue and earnings from operations at OptumInsight increased primarily due to organic growth and acquisitions in managed services, partially offset by decreased activity levels in volume-based services due to the impact of COVID-19 on payer and care provider clients.

21
Table of Contents
OptumRx
Revenue at OptumRx and the corresponding eliminations increased due to the inclusion of retail pharmacy co-payments. See Note 1 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report for further detail. Revenue at OptumRx also increased due to organic and acquisition growth in specialty pharmacy and new client wins, partially offset by an expected large client transition and lower script volumes driven by COVID-19 related care deferral, primarily related to first fill script volumes. Earnings from operations decreased primarily due to the impact of lower script volumes, partially offset by improved supply chain management. OptumRx fulfilled 316 million and 343 million adjusted scripts in the second quarters of 2020 and 2019, respectively. The decrease was due to the expected large client transition and lower script volumes due to the impacts of COVID-19, partially offset by organic growth.
LIQUIDITY, FINANCIAL CONDITION AND CAPITAL RESOURCES
Liquidity
Summary of our Major Sources and Uses of Cash and Cash Equivalents
 Six Months Ended June 30,Increase/(Decrease)
(in millions)202020192020 vs. 2019
Sources of cash:
Cash provided by operating activities$12,946  $9,108  $3,838  
Issuances of short-term borrowings and long-term debt, net of repayments
5,215  5,674  (459) 
Proceeds from common stock issuances870  448  422  
Customer funds administered
1,263  1,435  (172) 
Sales and maturities of investments, net of purchases573  —  573  
Other—  504  (504) 
Total sources of cash20,867  17,169  
Uses of cash:
Common stock repurchases(1,691) (4,501) 2,810  
Cash paid for acquisitions, net of cash assumed
(3,952) (4,751) 799  
Purchases of investments, net of sales and maturities —  (1,654) 1,654  
Purchases of property, equipment and capitalized software
(920) (977) 57  
Cash dividends paid
(2,212) (1,884) (328) 
Other(607) (529) (78) 
Total uses of cash(9,382) (14,296) 
Effect of exchange rate changes on cash and cash equivalents
(143) 6  (149) 
Net increase in cash and cash equivalents$11,342  $2,879  $8,463  
2020 Cash Flows Compared to 2019 Cash Flows
Increased cash flows provided by operating activities were primarily driven by increased net earnings as a result of the temporary deferral of care experienced at our benefits businesses related to COVID-19 and the timing of federal income tax payments, which will be paid in the third quarter. Other significant changes in sources or uses of cash year-over-year included decreased common stock repurchases and decreased net purchases of investments.
Financial Condition
As of June 30, 2020, our cash, cash equivalent, available-for-sale debt securities and equity securities balances of $60.3 billion included approximately $22.3 billion of cash and cash equivalents (of which $4.2 billion was available for general corporate use), $36.0 billion of debt securities and $2.0 billion of investments in equity securities. Given the significant portion of our portfolio held in cash and cash equivalents, we do not anticipate fluctuations in the aggregate fair value of our financial assets to have a material impact on our liquidity or capital position. Our available-for-sale debt portfolio had a weighted-average duration of 3.5 years and a weighted-average credit rating of “Double A” as of June 30, 2020. When multiple credit ratings are available for an individual security, the average of the available ratings is used to determine the weighted-average credit rating.
22
Table of Contents
Capital Resources and Uses of Liquidity
In addition to cash flows from operations and cash and cash equivalent balances available for general corporate use, our capital resources and uses of liquidity are as follows:
Commercial Paper and Bank Credit Facilities. Our revolving bank credit facilities provide liquidity support for our commercial paper borrowing program, which facilitates the private placement of unsecured debt through independent broker-dealers, and are available for general corporate purposes. For more information on our commercial paper and bank credit facilities, see Note 5 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.
Our revolving bank credit facilities contain various covenants, including covenants requiring us to maintain a defined debt to debt-plus-shareholders’ equity ratio of not more than 60%. As of June 30, 2020, our debt to debt-plus-shareholders’ equity ratio, as defined and calculated under the credit facilities, was approximately 39%.
Long-Term Debt. Periodically, we access capital markets and issue long-term debt for general corporate purposes, such as, to meet our working capital requirements, to refinance debt, to finance acquisitions or for share repurchases. For more information on our long-term debt, see Note 5 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.
Credit Ratings. Our credit ratings as of June 30, 2020 were as follows:
  
Moody’sS&P GlobalFitchA.M. Best
 RatingsOutlookRatingsOutlookRatingsOutlookRatingsOutlook
Senior unsecured debt
A3StableA+StableAStableA-Positive
Commercial paperP-2n/aA-1n/aF1n/aAMB-1n/a
The availability of financing in the form of debt or equity is influenced by many factors, including our profitability, operating cash flows, debt levels, credit ratings, debt covenants and other contractual restrictions, regulatory requirements and economic and market conditions, including the impacts of COVID-19 and related governmental market stabilization programs. A significant downgrade in our credit ratings or adverse conditions in the capital markets may increase the cost of borrowing for us or limit our access to capital.
Share Repurchase Program. During the six months ended June 30, 2020, we repurchased 6 million shares at an average price of $271.32 per share. As of June 30, 2020, we had Board authorization to purchase up to 66 million shares of our common stock.
Dividends. In June 2020, the Company’s Board of Directors increased the Company’s quarterly cash dividend to shareholders to an annual rate of $5.00 compared to $4.32 per share. For more information on our dividend, see Note 6 of Notes to the Condensed Consolidated Financial Statements included in Part 1, Item 1 of this report.
For additional liquidity discussion, see Note 10 of Notes to the Consolidated Financial Statements in Part II, Item 8, “Financial Statements and Supplementary Data” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part II, Item 7 in our 2019 10-K.
CONTRACTUAL OBLIGATIONS AND COMMITMENTS
A summary of future obligations under our various contractual obligations and commitments as of December 31, 2019 was disclosed in our 2019 10-K. During the six months ended June 30, 2020, there were no material changes to this previously disclosed information outside the ordinary course of business. However, we continually evaluate opportunities to expand our operations, including through internal development of new products, programs and technology applications and acquisitions.
RECENTLY ISSUED ACCOUNTING STANDARDS
See Note 1 of Notes to the Condensed Consolidated Financial Statements in Part I, Item 1 of this report for a discussion of new accounting pronouncements that affect us.

23
Table of Contents
CRITICAL ACCOUNTING ESTIMATES
In preparing our Condensed Consolidated Financial Statements, we are required to make judgments, assumptions and estimates, which we believe are reasonable and prudent based on the available facts and circumstances. These judgments, assumptions and estimates affect certain of our revenues and expenses and their related balance sheet accounts and disclosure of our contingent liabilities. We base our assumptions and estimates primarily on historical experience and consider known and projected trends. On an ongoing basis, we re-evaluate our selection of assumptions and the method of calculating our estimates. Actual results, however, may materially differ from our calculated estimates, and this difference would be reported in our current operations.
Our critical accounting estimates include medical costs payable and goodwill. For a detailed description of our critical accounting estimates, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part II, Item 7 in our 2019 10-K. For a detailed discussion of our significant accounting policies, see Note 2 of Notes to the Consolidated Financial Statements in Part II, Item 8, “Financial Statements and Supplementary Data” in our 2019 10-K.

FORWARD-LOOKING STATEMENTS
The statements, estimates, projections, guidance or outlook contained in this document include “forward-looking” statements which are intended to take advantage of the “safe harbor” provisions of the federal securities law. The words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “forecast,” “outlook,” “plan,” “project,” “should” and similar expressions identify forward-looking statements. These statements may contain information about financial prospects, economic conditions and trends and involve risks and uncertainties. Actual results could differ materially from those that management expects, depending on the outcome of certain factors including: risks associated with public health crises, large-scale medical emergencies and pandemics, such as the COVID-19 pandemic; our ability to effectively estimate, price for and manage medical costs; new or changes in existing health care laws or regulations, or their enforcement or application; the DOJ’s legal action relating to the risk adjustment submission matter; our ability to maintain and achieve improvement in quality scores impacting revenue; reductions in revenue or delays to cash flows received under government programs; changes in Medicare, the CMS star ratings program or the application of risk adjustment data validation audits; failure to maintain effective and efficient information systems or if our technology products do not operate as intended; cyber-attacks, other privacy/data security incidents, or our failure to comply with related regulations; risks and uncertainties associated with the pharmacy benefits management industry; competitive pressures; changes in or challenges to our public sector contract awards; our ability to contract on competitive terms with physicians, hospitals and other service providers; failure to achieve targeted operating cost productivity improvements; increases in costs and other liabilities associated with litigation, government investigations, audits or reviews; failure to manage successfully our strategic alliances or complete or receive anticipated benefits of strategic transactions; fluctuations in foreign currency exchange rates; downgrades in our credit ratings; our investment portfolio performance; impairment of our goodwill and intangible assets; and our ability to obtain sufficient funds from our regulated subsidiaries or from external financings to fund our obligations, maintain our debt to total capital ratio at targeted levels, maintain our quarterly dividend payment cycle, or continue repurchasing shares of our common stock. This above list is not exhaustive. We discuss these matters, and certain risks that may affect our business operations, financial condition and results of operations more fully in our filings with the SEC, including our reports on Forms 10-K, 10-Q and 8-K. By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. Actual results may vary materially from expectations expressed or implied in this document or any of our prior communications. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. We do not undertake to update or revise any forward-looking statements, except as required by law.
24
Table of Contents


ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We manage exposure to market interest rates by diversifying investments across different fixed-income market sectors and debt across maturities, as well as by endeavoring to match our floating-rate assets and liabilities over time, either directly or through the use of interest rate swap contracts. Unrealized gains and losses on investments in available-for-sale debt securities are reported in comprehensive income.
The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1% point or 2% points as of June 30, 2020 on our investment income and interest expense per annum, and the fair value of our investments and debt (in millions, except percentages):
June 30, 2020
Increase (Decrease) in Market Interest RateInvestment
Income Per
Annum (a)		Interest
Expense Per
Annum (a)		Fair Value of
Financial Assets (b)		Fair Value of
Financial Liabilities
2 %$504  $200  $(2,567) $(8,573) 
1252  100  (1,271) (4,715) 
(1)(80) (16) 623  4,676  
(2)(80) (16) 657  6,214  
(a)  Given the low absolute level of short-term market rates on our floating-rate assets and liabilities as of June 30, 2020, the assumed hypothetical change in interest rates does not reflect the full 100 and 200 basis point reduction in interest income or interest expense, as the rate cannot fall below zero.

(b)  As of June 30, 2020, some of our investments had interest rates below 1% so the assumed hypothetical change in the fair value of investments does not reflect the full 100 and 200 basis point reduction.
ITEM 4. CONTROLS AND PROCEDURES
EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES
We maintain disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (Exchange Act) that are designed to provide reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in SEC rules and forms; and (ii) accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
In connection with the filing of this quarterly report on Form 10-Q, management evaluated, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of our disclosure controls and procedures as of June 30, 2020. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2020.
CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING
There have been no changes in our internal control over financial reporting during the quarter ended June 30, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
A description of our legal proceedings is included in and incorporated by reference to Note 7 of Notes to the Condensed Consolidated Financial Statements contained in Part I, Item 1 of this report.
25
Table of Contents

ITEM 1A. RISK FACTORS
In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item 1A, “Risk Factors” of our 2019 10-K and Part II, Item 1A, “Risk Factors” of our 10-Q for the quarterly period ended March 31, 2020 (“2020 First Quarter 10-Q”), which could materially affect our business, financial condition or future results. The risks described in our 2019 10-K and 2020 First Quarter 10-Q, are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results.
There have been no other material changes to the risk factors as disclosed in our 2019 10-K and 2020 First Quarter 10-Q.
ITEM 2. UNREGISTERED SALE OF EQUITY SECURITIES AND USE OF PROCEEDS
In November 1997, our Board of Directors adopted a share repurchase program, which the Board evaluates periodically. There is no established expiration date for the program. During the second quarter 2020, we did not repurchase any shares of our common stock. As of June 30, 2020, we had Board authorization to purchase up to 66 million shares of our common stock.
26
Table of Contents
ITEM 6. EXHIBITS*
The following exhibits are filed or incorporated by reference herein in response to Item 601 of Regulation S-K. The Company files Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K pursuant to the Securities Exchange Act of 1934 under Commission File No. 1-10864.
3.1
3.2
4.1
4.2
4.3
4.4
10.1
10.2
10.3
10.4
10.5
31.1
32.1
101.INSXBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCHInline XBRL Taxonomy Extension Schema Document.
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document.
101.LABInline XBRL Taxonomy Extension Label Linkbase Document.
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document.
104  Cover Page Interactive Data File (formatted as Inline XBRL and embedded within Exhibit 101).
 ________________
*Pursuant to Item 601(b)(4)(iii) of Regulation S-K, copies of instruments defining the rights of certain holders of long-term debt are not filed. The Company will furnish copies thereof to the SEC upon request.
27
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
UNITEDHEALTH GROUP INCORPORATED
 
/s/ DAVID S. WICHMANN
Chief Executive Officer
(principal executive officer)		Dated:July 31, 2020
David S. Wichmann  
/s/ JOHN F. REX
Executive Vice President and
Chief Financial Officer
(principal financial officer)		Dated:July 31, 2020
John F. Rex  
/s/ THOMAS E. ROOS
Senior Vice President and
Chief Accounting Officer
(principal accounting officer)		Dated:July 31, 2020
Thomas E. Roos  
28

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-Q’ Filing    Date    Other Filings
1/1/21
Filed as of:8/3/20
Filed on:7/31/20
7/30/20
For Period end:6/30/204
3/31/2010-Q
1/1/20
12/31/1910-K,  11-K
6/30/1910-Q
3/31/1910-Q
1/1/19
2/12/184
2/15/174,  S-8 POS
2/14/174,  NO ACT,  SC 13G/A
 List all Filings 

1 Subsequent Filing that References this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/01/21  UnitedHealth Group Inc.           10-K       12/31/20  107:17M

7 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 6/01/20  UnitedHealth Group Inc.           S-8         6/01/20    5:292K
 8/16/17  UnitedHealth Group Inc.           8-K:5,9     8/16/17    3:277K
 7/01/15  UnitedHealth Group Inc.           8-A12B/A               3:192K
 2/04/08  Unitedhealth Group Inc.           S-3ASR      2/04/08    9:842K                                   Donnelley … Solutions/FA
 8/06/07  Unitedhealth Group Inc.           10-Q        6/30/07    8:917K                                   Donnelley … Solutions/FA
11/13/01  Unitedhealth Group Inc.           10-Q        9/30/01    4:254K                                   Toppan Merrill-FA2/FA
 1/11/99  Unitedhealth Group Inc.           S-3/A                 30:1.5M                                   Donnelley … Solutions/FA
↑Top
Filing Submission 0000731766-20-000042   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Sat., Apr. 20, 10:51:23.2am ET